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Abstract  
Sarcopenia is a geriatric syndrome of reduced muscle mass and physical performance 
associated with falls, fractures, impairments in activities of daily living, and mortality. 
Hip fractures are fractures of the upper third of the femur and typically occur in older 
persons after a fall. They are associated with lifelong impairments of mobility, 
mortality and risk of institutionalization. Hip fractures are common, preventable and in 
many places receive suboptimal care. This thesis is based on the research project 
sarcopenia in patients with hip fracture. The project is a prospective study with one-
year follow-up on older acute hip fracture patients living in the community, admitted 
at three hospitals: Haraldsplass Deaconess Hospital and Haukeland University 
Hospital in Bergen and Diakonhjemmet Hospital in Oslo, Norway in the period of 
2011-2013. The aim of this thesis is to investigate sarcopenia as a clinically useful risk 
factor for adverse clinical outcomes after hip fracture. 
 
Our findings are presented in four papers. In the first paper we studied anthropometry 
and bioelectrical impedance analysis for determining muscle mass in patients with hip 
fracture, using dual-energy X-ray absorptiometry as the reference method. We found 
that muscle mass measured by single frequency bioelectrical impedance and 
anthropometry can identify patients with low muscle mass, which is a necessary step 
in assessing sarcopenia at the bedside. 
 
In the second paper we investigated how hip fracture, surgical repair and surgical 
implants affected measurements by bioelectrical impedance analysis. Bioelectrical 
impedance analysis on the same side of the body as the fracture was affected in the 
days after surgery, but not after three months. Measurements by bioelectrical 
impedance analysis were not affected by type of surgical implant. Our findings support 
the use of bioelectrical impedance analysis in subjects who live with surgical implants 
and after surgery. We recommend measuring the unfractured side if bioelectrical 
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impedance analysis is used to determine body composition in the days after hip 
fracture surgery. 
 
In the third paper, we assessed the feasibility of determining sarcopenia in 
postoperative patients with hip fracture, and the prevalence of sarcopenia. Sarcopenia 
status, estimated by anthropometry, grip strength and self-reported pre-fracture 
mobility, was assessed in 202 out of 282 participants. The prevalence of sarcopenia 
was 37% and associated with increasing age, comorbidities and malnutrition. There 
was no difference in the prevalence of sarcopenia by sex, but men with hip fracture 
had a higher prevalence of low muscle mass. Our findings support sarcopenia as a 
clinically relevant risk factor after hip fracture. 
 
In the fourth paper, we investigated how sarcopenia status predicted change in 
mobility and other clinical outcomes at one year after hip fracture. Sarcopenia did not 
predict change in mobility. Participants with sarcopenia had lower mobility and more 
impairments in activities of daily living and an increased risk of becoming a resident 
of a nursing home and death. Pre-fracture mobility predicted mobility at one year. 
Sarcopenia needs further validation in patients with hip fracture by exploring other 
definitions, techniques and cut-points in order to estimate future risk and provide 
personalized medicine. We recommend that all hip fracture patients have their pre-
fracture mobility assessed to determine their risk of adverse outcomes and as a 
benchmark for successful rehabilitation. 
 
This thesis expands the knowledge about sarcopenia to a vulnerable group of patients. 
Our findings support sarcopenia as a clinically relevant risk factor in acute hip fracture 
patients. Determining sarcopenia is feasible, it is prevalent in patients with hip fracture 
and it is associated with comorbidities, malnutrition, mobility and becoming a resident 
of a nursing home.  
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Sammendrag på norsk  
Sarkopeni er en aldersrelatert tilstand hvor personer har lite muskelmasse, redusert 
muskelstyrke og redusert fysisk yteevne, noe som er assosiert med fall, brudd, redusert 
evne til å klare seg selv i dagliglivet og økt fare for død. Hoftebrudd er brudd i øverste 
del av lårbenet og skjer typisk hos eldre etter et fall fra egen høyde. Hoftebrudd er 
assosiert med varig nedsatt gangfunksjon, økt dødelighet og økt fare for å komme på 
sykehjem. Hoftebrudd er vanlig, kan forhindres, og mange pasienter med hoftebrudd 
får ikke optimal behandling. Denne doktorgradsavhandlingen er basert på 
forskningsprosjektet sarkopeni hos pasienter med hoftebrudd. I denne studien har vi 
undersøkt sammenhengen mellom sarkopeni, hoftebrudd og gangfunksjon hos 282 
pasienter innlagt med hoftebrudd ved Haraldsplass Diakonale sykehus, Haukeland 
universitetssjukehus og Diakonhjemmet sykehus i årene 2011-2013, med ett års 
oppfølging. Vår hypotese er at sarkopeni er en relevant risikofaktor for dårlig prognose 
etter hoftebrudd. 
 
Avhandlingen består av fire artikler. I den første artikkelen ønsket vi å finne enkle 
måter å fastslå muskelmasse etter hoftebruddet. Vi sammenlignet bioelektrisk 
impedans og antropometri med røntgengjennomlysning. Vi fant at antropometri og 
bioelektrisk impedans var i stand til å identifisere deltagerne som hadde lav 
muskelmasse, noe som er nødvendig for å kunne fastslå sarkopeni hos sengeliggende 
pasienter. 
 
I den andre artikkelen analyserte vi hvordan hoftebrudd og kirurgi påvirket målinger 
med bioelektrisk impedans. Målinger ved bruk av bioelektrisk impedans utført på 
samme kroppshalvdel som hoftebruddet ble påvirket i dagene etter hoftebruddet, men 
ikke etter tre måneder. Målingene ble ikke påvirket av typen kirurgisk implantat som 
ble benyttet. En praktisk løsning på dette er å måle den motsatte kroppshalvdelen til 
hoftebruddet. Bioelektrisk impedans kan brukes hos pasienter med kirurgiske 
implantater og hos pasienter som nylig har gjennomgått hoftebrudd. 
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I den tredje artikkelen undersøkte om det er mulig å fastslå sarkopeni hos 
postoperative pasienter med hoftebrudd og prevalensen av sarkopeni hos disse. Vi 
undersøkte for sarkopeni ved å bruke antropometri, gripestyrke og selvrapportert 
gangfunksjon hos 202 av 282 deltagere og fant at 37 % hadde sarkopeni. Sarkopeni 
var mer vanlig ved økende alder, hos dem med flere kroniske sykdommer eller med 
tegn til underernæring. Det var ingen forskjell i forekomsten av sarkopeni mellom 
kvinner og menn, men menn med hoftebrudd hadde økt risiko for å ha lav 
muskelmasse. Disse funnene understøtter at sarkopeni er en relevant risikofaktor hos 
pasienter med hoftebrudd. 
 
I den fjerde artikkelen undersøkte vi om sarkopeni fører til at gangfunksjonen 
forverres ett år etter hoftebruddet. Sarkopeni fører ikke til ytterligere forverring av 
gangfunksjonen, men gangfunksjonen var dårligere hos dem med sarkopeni 
sammenlignet med dem uten. Sarkopeni var forbundet med redusert evne til klare 
dagliglivets aktiviteter og økt risiko for å komme på sykehjem eller død. Vi anbefaler 
at det forskes mere på sarkopeni hos pasienter med hoftebrudd ved å utvikle andre 
måter å måle sarkopeni på, til bruk i risikovurdering og til persontilpasset behandling. 
Vi anbefaler at gangfunksjonen før bruddet brukes til å forutsi fremtidig gangfunksjon 
og brukes som et mål på vellykket rehabilitering. 
 
Denne doktorgradsavhandlingen har bidratt til å belyse forekomsten av sarkopeni hos 
pasienter med hoftebrudd. Den har vist at sarkopeni er mulig å måle, er assosiert med 
komorbiditet, underernæring, redusert gangfunksjon og økt risiko for å flytte på 
sykehjem. Våre funn styrker hypotesen om at sarkopeni er en relevant risikofaktor for 




Good health is associated with having a reserve capacity that enables us to tolerate 
injury. As we grow older our bodies undergo a dynamic process of damage and repair. 
With increasing age, we accumulate injuries which lead to increased vulnerability, loss 
of function, disablement, illness and eventually to death (1, 2). The resources and 
mechanisms that prevent or slow this process of disablement are multifactorial and 
dependent on factors intrinsic, and extrinsic to the individual. Examples of bodily 
reserves are excess lung capacity reducing the frequency of respiratory failure in 
pneumonia and good cognitive function reducing the risk of delirium after surgery. 
Motivation, health literacy, leisure time, money, and a physical environment that 
enable an intellectual, physical, social and emotional fulfilling life are also factors that 
protect against developing disability. If injury and illness occur, these same factors 
facilitate healing and rehabilitation, and minimize the risk of the injury or illness 
recurring (3). Several conceptual models have been developed for the process of 
health, illness and disability, among them the one by Verbrugge and Jette reproduced 
in figure 1 (2), and the World Health Organization International Classification of 
Functioning, Disability and Health (3). 
 
 
Figure 1: The disablement process. After Verbrugge and Jette (2). 
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Loss of mobility is a common, age-related condition that is closely associated with 
disability (4). One quarter of the Norwegian population aged ≥67 report that they are 
unable to walk for 5 minutes or ascend a flight of stairs without pausing (5). This 
thesis is about how two age-related phenomena, sarcopenia and hip fractures, 
contribute to poor health. Sarcopenia is the loss of muscle mass and physical function, 
and is associated with falls, fractures (6) and loss of mobility (7). Hip fractures are 
common fall-related injuries leading to a loss of mobility (8). In the disablement 
process described by Verbrugge and Jette (2), sarcopenia and hip fracture are 
pathological processes which lead to reduced mobility, functional limitations and 
disability. This thesis examines sarcopenia in acute hip fracture patients, included at 
three Norwegian hospitals and followed for one year. 
 
 
1.1 Hip fracture 
Mrs. Olsen, 82 years old, trips and falls during a bathroom visit. She is not 
able to react quickly enough to regain her balance and she lands on the lateral 
aspect of her left hip. Unable to get up from the floor, she calls for an 
ambulance and is taken to hospital. She is given morphine and has an X-ray of 
her hip. The X-ray shows an undisplaced fracture of the neck of femur. Mrs. 
Olsen is operated on in spinal anesthesia the next morning and receives two 
pins to stabilize the fracture in the anatomical position. After 6 days in hospital 
she is discharged to the rehabilitation ward of a skilled nursing home. She 
spends another four weeks there before returning home. At home, she receives 
weekly care visits for help in showering and managing her medication. Her 
walking ability slowly improves over the next year, but she rarely moves out of 
the house and is dependent on her rollator. 
 
1.1.1 Etiology of hip fractures 
A hip fracture is a fracture of the upper part of the femur (including the neck of femur, 
trochanter and sub-trochanteric region). See figure 2. They usually result from a 
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sideways fall from standing height or lower with the impact on the greater trochanter 
(9, 10).  
 
 
Figure 2: Proximal femur indicating types of hip fractures. Image by Mikael 
Häggström. In the public domain. 
 
A person who has lost their balance and is about to fall will usually be able to 
undertake protective maneuvers such as landing on the outstretched arm or turning 
their upper body in the direction of the fall to prevent fractures and other traumatic 
injuries (9, 11). Many falls are caused by extrinsic factors, such as trips or stumbles 
(12) and in 15% of falls the cause would also have led a fit person to fall (13). Some 
falls have a single precipitating cause such as symptomatic orthostatic hypotension, 
acute stroke with paralysis, or other acute illness (14), but most falls are the result of 
several interacting causes (15). Falls are common in the older population with 1/3 of 
the population aged >65 years experiencing a fall each year, and 50% of the 
population aged >80 years falling each year. About 10% of persons who fall suffer 
serious injuries and 2% suffer a hip fracture (16).  
 
Risk factors for falls and fractures  
Risk factors for hip fracture can be organized into risk factors for falls and risk factors 
related to bone quality (17). See table 1. There are several risk predictions scores for 
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fractures such as the FRAX score, QFracture and the Garvan (18). These include risk 
factors such as female sex, age, body mass index (BMI), prior fragility fracture, 
previous falls, current tobacco smoking, use of oral glucocorticoids, comorbidities, 
secondary causes of osteoporosis, alcohol consumption and bone mineral density. 
 
The risk factors for falls include previous falls, reduced mobility, vertigo, Parkinson’s 
disease or use of antiepileptic drugs (19). The European Union Geriatric Medicine 
Society recommends screening older adults for risk of falls and bone fragility and one 
study found that using sarcopenia assessment with FRAX can improve the prediction 
of fracture risk (20). Current guidelines do not recommend determining sarcopenia to 
estimate the risk of hip fracture (21). 
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Table 1. Risk factors for falls and fractures 
 
 
Risk factors for falls  Risk factors for fractures 
Female gender X  X 
Maternal hip fracture   X 
Increasing age X  X 
Low BMI X  X 
Weight loss   X 
Low bone mineral density   X 
Low gait speed X   
Previous falls X   
Previous fracture   X 
Reduced muscle strength X  X 
Inappropriate medications X   
Functional impairment X   
Use of walking aid X   
Cognitive impairment X   
Poor balance X   
Depression X   
Poor self-rated health   X 
Table 1. Adapted from papers by Tinetti and Kumar and Cummings et al (22, 
23). 
 
1.1.2 Epidemiology of hip fractures 
Hip fractures are an important cause of poor health and early death in older persons 
(24, 25). There are approximately 9,000 hip fractures a year in Norway (26). The 
incidence in Norway is among the highest in the world (27) with an age-adjusted rate 
of 74 per 10,000 person-years in women and 35 per 10,000 person-years in men (28) 
and a lifetime risk of hip fracture of 18% in men and 30% in women (29). Most occur 
in women older than 80 years (28). Approximately 25% of all patients are residents of 
a nursing home before the fracture (30). The causes of the high incidence of hip 
 19 
fractures in Norway compared to other countries are undetermined (28). The cost of 
health care and social services for a patient living in the community before the fracture 
is estimated at 500,000 NOK in the first year increasing to 1,000,000 NOK after two 
years (31). 
 
1.1.3 Consequences of hip fracture 
A hip fracture has been described as “a life breaking event” by patients, with feelings 
of vulnerability, dependency and disruption of normal life (32). Prognosis after hip 
fracture is related to the vulnerability of the patient, the fracture itself, and the 
treatment she receives. This includes surgery, rehabilitation and interventions to 
reduce the risk of adverse outcomes. A hip fracture is painful and the average pain 
score in the emergency department is 7 on a scale from 0 to 10 (33). Around 30% of 
the patients have pain and trouble sleeping due to pain 6 months after the fracture (34). 
Good pre-fracture mobility and self-reported health are strong determinants of 
successful recovery of mobility, whereas poor mobility increases the risk of becoming 
dependent in activities of daily living and becoming a resident of a nursing home (35). 
It takes 6-12 months before maximal recovery of mobility is achieved, but half of all 
patients do not regain their pre-fracture level of mobility (8, 36). Geriatric ward care 
(37) and extended progressive strength training improves mobility (38). Fear of falling 
is a condition where concern about falling leads one to avoiding activities that could 
lead to a fall (39). After hip fracture around half of patients suffer from a fear of falling 
(40). Fear of falling is associated with falls, impairments in activities of daily living, 
not being able to walk outdoors, becoming a resident of a nursing home. and mortality 
(41). Physical exercise and geriatric care reduces the fear of falling (42, 43). A hip 
fracture leads to a reduced quality of life and impairments in activities of daily living 
(8, 44). Around half of the patients will need assistance in their own home and 20-30% 
will lose the ability to make their own meals (8). Among those who live in their own 
home before the fracture, 15% become residents of a nursing home after the fracture 
and up to half will have moved to some sort of supported living arrangement (8). Some 
10% of the patients are readmitted to hospital within 30 days of discharge (45). 
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Approximately 10% of patients undergo revision hip surgery (46). A fracture is a risk 
factor for subsequent fractures (47). In Norway, it is estimated that the 10 year risk of 
a second hip fracture is 15% for women and 11% for men (48). Mortality in the year 
after hip fracture is 10-30% (25) which is greater than for myocardial infarction and 
similar to that of stroke (49). Risk factors for mortality are male gender, increasing 
age, higher American society of Anesthesiologists (ASA) score, greater number of 
comorbidities, malnutrition, and limitations in activities of daily living (50). Common 
causes of death in hospital after hip fracture are pneumonia, heart failure, myocardial 
infarction and pulmonary embolism (51). In younger patients the relative risk ratio for 
mortality is increased, but the absolute increase in risk is greater in older patients (52). 
It is estimated that the excess mortality of patients with hip fracture constitute 5% of 
the mortality in the Norwegian population aged 50 years and older (25). Hip fractures 
account for a loss of 2.7% of the healthy life expectancy in older persons, which is of 
the same magnitude as breast cancer (24). 
 
1.1.4 Treatment of hip fractures 
Reducing the burden of hip fracture requires reducing the risk of having a hip fracture, 
optimal acute treatment, good rehabilitation and preventing complications (53). 
Surgery is the primary treatment of hip fracture (54). When the proximal femur is 
fractured the tension of the surrounding muscles pull the parts of the femur apart. 
Surgical treatment involves restoring normal anatomy by fixing the fracture in place 
with surgical implants to restore mobility and reduce pain. Surgical implants are 
mainly composed of metal and sometimes have plastic, hydroxyapatite or ceramic 
components. See figure 3 and 4 for commonly used surgical implants in treatment of 





Figure 3: Surgical implants used for hip fracture repair. From left: 
hemiarthroplasty of the hip, two cannulated screws and a compression hip 
screw. Photo: Ole Martin Steihaug. 
 
 
Fig. 4: Plain film X-rays of hip fractures treated with surgical implants. From 
JED. Gjertsen (55). Reproduced with permission. 
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Treatment has undergone substantial changes in the last decades with a reduction in 
rates of reoperations and mortality in the period 2005-2014 reported in a study from 
the Norwegian Hip Fracture Register (56). The quality of treatment in Norway is 
comparable to other developed countries. The 30-day mortality rate after admission for 
acute hip fracture is at 8% (57) compared to 7% in England and Wales (58).  
 
Orthogeriatric care of hip fractures 
Orthogeriatric care is the current best practice care for patients with hip fracture (53). 
Orthogeriatrics is shorthand for the multidisciplinary collaboration between orthopedic 
surgeons, geriatricians and other healthcare worker in the care of older patients with 
fractures. Comprehensive geriatric assessment is a cornerstone of geriatric treatment. It 
is the process of identifying the patient’s preferences and challenges and to improve 
outcomes by managing complications, rehabilitation, comorbidities, medications and 
preventing falls (59). Studies have shown less delirium (43), better physical 
performance (43), economic benefits (43) and reduced mortality (60) for patients 
receiving orthogeriatric care compared to traditional orthopedic care. Orthogeriatric 
care is slowly becoming more common in Norway after two important intervention 
trials (43, 61). The Oslo Orthogeriatric Trial (61) was a randomized intervention study 
of orthogeriatric care compared to orthopedic care. The hypothesis was that 
orthogeriatric care would lead to improved cognition after 4 months. There was no 
effect of orthogeriatric care on cognition, but a beneficial effect on physical 
performance for participants living in the community. The Trondheim hip fracture trial 
found that the participants who received orthogeriatric care had better physical 
performance at four months (43). This difference was maintained at 12 months and 
was more pronounced among younger, female patients with less impairments in in 
activities of daily living before the fracture (62). 
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Rehabilitation and aftercare 
With the increasing age of the population, older persons are living longer with reduced 
mobility and other complications of hip fracture (52). Progressive strength training and 
other forms of exercise rehabilitation for several months after hip fracture improves 
physical performance (63). One small study found that close follow-up by a 
geriatrician and physical exercise in the year after hip fracture improved physical 
performance, independence in activities of daily living, and reduced the risk of nursing 
home admission and mortality (64). Reducing the risk of falls by exercise programs 
leads to a reduced risk of fracture (65) and is supported by the European Union 
Geriatric Medicine Society (21). Supplemental vitamin D and calcium provides a 
small reduction in the risk of fractures (66). Hip protectors, padded underwear, reduce 
the risk of hip fracture for persons living in institutions (67). Fractures can be 
prevented by targeted screening and treatment of osteoporosis (68). This is also true 
for second hip fractures (69). Use of anti-osteoporosis drugs reduces the risk of hip 
fracture by 30-50% (70, 71). Among Norwegian hip fracture survivors living in the 
community 4% of men and 15% of women received a prescription for an anti-
osteoporosis drug in 2005 (72). This compares unfavorably with the UK, where 97% 
of patients are considered for drug treatment (58). 
 
1.2 Sarcopenia  
Mrs. Olsen is evaluated in the orthopedic ward 4 days after surgery for hip fracture. 
She can rise from a chair with assistance and walk slowly along the hallway using a 
rollator and a member of staff by her side to support in case she loses her balance. 
Her handgrip strength is 14kg and her appendicular lean mass by anthropometry is 
5kg/m2. She has sarcopenia. What are the implications of her sarcopenia diagnosis? 
How does sarcopenia status differ from nutritional risk and frailty?  
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Sarcopenia is associated with falls and falls are associated with hip fracture. 
Sarcopenia is an age-related decline in muscle mass and physical function (73). 
Skeletal muscle can be considered an organ constituting 40% of the body weight and 
requiring 30% of basal energy expenditure. Skeletal muscle enables locomotion, 
manipulation of the environment, breathing, communication, thermoregulation and is a 
nutrient store (74). Sarcopenia is a risk factor for reduced mobility and death (7). 
Sarcopenia has received increasing attention since it was described by Irwin 
Rosenberg in 1988 (75). It was originally described as a syndrome of reduced muscle 
mass (75), but definitions have developed to also included reduced strength and 
reduced physical performance (76). Janssen et al defined sarcopenia as low muscle 
mass relative to body mass (73), the European Working Group on Sarcopenia in Older 
Persons (EWGSOP) defined sarcopenia as low muscle mass and either low muscle 
strength or physical function (77). The Foundation of the National Institute of Health 
(FNIH) sarcopenia project defined sarcopenia as low muscle mass with low muscle 
strength (78). Sarcopenia has recently been recognized as a health related condition 
with its own International Classification of Diseases code, M62.84 (79). The 
EWGSOP definition describes primary and secondary sarcopenia. Primary sarcopenia 
has no evident cause, except for aging. Secondary sarcopenia is a result of identifiable 
processes such a malnutrition, bed-rest or chronic diseases.   
 
1.2.1 Pathophysiology of sarcopenia 
The pathophysiology of sarcopenia is complex and only partially determined (80).  
Physical performance is made possible by the interaction of several organs and 
systems. Physical performance and sarcopenia is influenced by hereditary (81) as well 
as environmental factors (82). Sarcopenia status is influenced by socioeconomic status 
and depressive symptoms (83, 84) as well as specific behaviours such as excessive 
alcohol intake (85) or smoking (86). An important feature is the relative loss of type 2 
muscle fibres, which are known as “fast twitch” fibres that are important for explosive 
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muscle contraction necessary to prevent falls (87). Chronic low grade inflammation is 
associated with sarcopenia, possibly by disturbing the balance of protein synthesis and 
catabolism (88), leading to anorexia, proteolysis and lipolysis. The endocrine system 
causes sarcopenia by influencing muscle metabolism and inflammation (89). 
Deficiencies in the sex hormones estrogen and testosterone, growth hormone, thyroid 
hormone, PTH and vitamin D are associated with sarcopenia (89, 90). The prevalence 
of obesity, diabetes mellitus type 2 and sarcopenia all increase with increasing age 
(91). Muscle is one of the most important regulators of blood glucose (92), and loss of 
muscle mass leads obesity and diabetes mellitus type 2 that are associated with a 
further loss of muscle mass (93). Several brain functions are necessary for performing 
physical activity such as motivation and alertness, initiation of movement, sensation 
and perception, and coordination of movement (94). Examples of diseases contributing 
to sarcopenia by acting on the brain are Alzheimer dementia, Parkinson disease and 
stroke. The brain is dependent on the peripheral nervous system for transmitting the 
signals from the brain to the muscles by the neuromuscular junction, which undergoes 
a process of degeneration leading to loss of motor units and motor fibres (95). The 
muscles and nervous system are dependent on blood flow by the cardiovascular 
system, which can be affected by heart failure or atherosclerotic disease (96). At the 
level of the muscle, sarcopenia is associated with a reduced pool of satellite cells 
leading to lower regenerative potential after injury (97) and reduced capillarization of 
skeletal muscle, leading to impaired transport of nutrients and waste products (98). 
 
1.2.2 How to diagnose sarcopenia 
Sarcopenia is not currently a routine part of diagnosis, prognostication or treatment, 
but several expert groups recommend that it should be (73, 77, 99, 100). The 
recommended approach is to first determine physical performance, then muscle 
strength and lastly muscle mass, only moving on to the next step if the result of the 
previous step is abnormal. In this thesis we have adhered to the recommendations of 
the EWGSOP that to have sarcopenia one must have low muscle mass and one of 
either low muscle strength or physical function (73).  
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Measuring muscle mass  
Low muscle mass is mandatory for diagnosing sarcopenia (73). It can also be the 
aspect of sarcopenia which is most difficult to measure. In this thesis we have assessed 
appendicular lean mass (ALM), which typically constitutes 75% of total body muscle 
mass (101). Typical values for ALM are 23kg for older men and 16kg for older 
women (77). Muscle mass varies with body size, and this has led to different 
approaches to define low muscle mass relative to body size such as ALM/weight, 
ALM/height2 and ALM/BMI, or muscle mass relative to fat mass (102).There is 
disagreement about what technologies are precise enough to measure muscle mass, 
while still being feasible in clinical use. Dual-energy X-ray absorptiometry (DXA) 
measures lean mass as a function of how the body stops X-ray beams of two different 
energy levels. This creates a two-dimensional image where bone is white, fat is dark 
and lean mass is grey. DXA is used to determine total body muscle mass by assessing 
the non-bone, non-fat compartment of the arms and legs known as ALM (103). The 
radiation exposure of a whole body DXA scan is comparable to one day of background 
radiation at sea level (104). ALM by DXA has good precision with a coefficient of 
variation of 3% (105), and muscle mass by DXA will usually be within 2kg of that 
measured by magnetic resonance imaging (MRI) (106, 107). DXA has been used to 
detect small changes in muscle mass in repeated measures (108). Muscle mass by 
DXA is sensitive to changes in muscle water content, such as seen with dehydration 
(109) or carbohydrate loading (109). The European Society for the Clinical and 
Economic Aspects of Osteoporosis and Osteoarthritis working group on frailty and 
sarcopenia have recently stated that DXA is the reference standard for measuring 
muscle mass (101). 
 
Anthropometry is an established and commonly used method for determining body 
composition (110). The most widely used anthropometric method is to determine BMI, 
as body weight divided by height squared. Measuring weight and height can be 
challenging in patients who are immobile in bed. Using BMI, one can estimate the 
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presence of a large fat mass compartment in cases with high BMI, and low muscle 
mass and low-fat mass with a low BMI. More advanced anthropometric techniques 
involve measuring the circumference of different body parts, such as the upper arm, 
calves, or the abdomen, and skinfold thicknesses with calipers. In obese subjects with 
large amounts of superficial adipose tissue it is challenging to estimate skinfolds 
accurately (111). Test-retest correlation coefficient of variability is typically 10% for 
triceps skinfold and 1% for midarm circumference (112). Anthropometry for 
determining muscle mass has been validated using MRI (113), DXA, urinary 
creatinine excretion (112) and underwater weighing (114). Muscle mass estimated by 
anthropometry is usually within 6kg of muscle mass measured by MRI (113).  
 
Bioelectrical impedance analysis (BIA) is a technique for measuring body composition 
based on how a weak alternating current is affected by moving through the body (115). 
Body fat has high resistance, whereas muscle is a conductor. BIA is an established 
technology for determining muscle mass and is in common use by laypersons and 
geriatricians (110, 116). It is safe, non-invasive, quick and inexpensive. BIA is highly 
reproducible with a reported coefficient of variation of 1-2% within one day for 
resistance (115). Several epidemiological studies have used BIA to determine muscle 
mass (117), and it is able to determine muscle mass at a group level (118). BIA has 
poor precision in determining serial changes in muscle mass as seen in studies on 
persons undergoing exercise interventions, weight loss or hemodialysis (119-121). A 
systematic review cautioned against using BIA to detect changes in muscle and 
estimated that BIA could detect a change in the mass of a body compartment of 2kg 
(122). The typical changes in ALM seen in intervention studies are smaller than this 
and are frequently less than 1kg (123). Expert opinion recommends that BIA is used as 
a screening tool to identify persons with low muscle mass (124). Different BIA 
devices have different number and placement of electrodes on the body, use different 
frequencies, voltages and currents, and have the patient standing or lying. Many BIA 
devices use proprietary algorithms for converting their electrical measurements into 
estimates of body composition. For this thesis we have used single frequency BIA 
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devices with four electrodes, converting the raw electrical measurements of resistance 
and reactance into ALM. 
 
Other methods for determining muscle mass are computerized axial tomography (CT), 
ultrasound and creatinine excretion. CT enables quantification of individual muscle 
size, density and amount of fat infiltration (114). CT involves a greater radiation 
exposure compared to DXA. Ultrasound can accurately measure the cross-section of 
superficial skeletal muscles such as the rectus femoris muscle (125). It can be used at 
the bedside and the sensitivity to change is good (126). Historically, the excretion of 
creatinine in urine measured over several days has been used to estimate muscle mass 
(114).  
 
Measuring muscle strength 
Handgrip strength is a surrogate measure of whole body muscle strength and has been 
shown to have good test characteristics (127). The clinically important difference in 
grip strength has been proposed to be 6kg (127). The Southampton protocol describes 
how one should measure grip strength (127), but it is not uniformly used (110). 
Handgrip strength is the only recommended method for measuring muscle strength by 
the EWGSOP and the FNIH sarcopenia project (73, 77). The FNIH sarcopenia project 
recommends cut-points for low grip strength of <16kg for women and <26kg for men, 
whereas the EWGSOP recommends <20kg for women and <30kg for men. There is 
some confusion in the literature whether the EWGSOP cut points should be 
operationalized as <20kg and <30kg, or ≤20kg and ≤30kg, but the practical difference 
is minimal. The cut-points of ≤20kg and ≤30kg have been used in 16 out of 17 studies 
on European populations (110) and are the cut-points used in this thesis. There is 
interest in using lower extremity strength instead of handgrip strength, but this is not 
current practice (128).  
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Measuring physical performance 
Physical performance, such as gait speed, is strongly predictive of future adverse 
events (129). Studenski et al described a continuous graded influence of habitual 
walking speed on mortality risk (130) and that improvement in walking speed led to 
reduced mortality (131). The EWGSOP recommends several different objectively 
measured methods for determining physical performance such as the Short Physical 
Performance Battery, usual gait speed, Timed get-up-and-go test and the Stair climb 
power test (73). The EWGSOP does not consider how to determine physical 
performance in cases where objective tests are challenging, such as in acute hip 
fracture.  
 
1.2.3 Epidemiology and natural progression of sarcopenia 
Maximal muscle mass is achieved at age 20-40 years and remains stable until age 70 
years, when it starts to slowly decline. Muscle strength has a more rapid decline with 
age compared to muscle mass (132). Older men have more muscle mass and are 
stronger than women of the same age (133). There are differences in muscle mass by 
geographical region with muscle mass being lower in individuals from Asian 
populations, compared to European populations (134). The prevalence of sarcopenia 
has been studied in older persons living in the community, in institutions and in 
hospitals (135). Mijnarends et al, reporting on a population-based study from Iceland, 
found an increase in the prevalence of sarcopenia from 7% to 17% from age 75 to 80 
years and that engaging in moderate and vigorous physical activity prevented the 
development of sarcopenia (136). A systematic review on the prevalence of sarcopenia 
by EWGSOP criteria found a prevalence of 1-29% in persons living in the community, 
14-33% in those living in long-term care institutions and 10% for those in acute 
hospital care (78). Jacobsen et al found a prevalence of sarcopenia of 30% in a 
Norwegian population of hospitalized older persons (137). In most of these studies the 
prevalence of sarcopenia increased with age, but the effect of sex varied.  
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1.2.4 Related syndromes 
Frailty 
Frailty is a syndrome characterized by increased vulnerability to stressors like illness 
and trauma and is used for evaluating the health of an older person beyond what is 
possible by age, disease severity or comorbidities. Frailty is more common in women 
and the prevalence increases with age (138). There are several definitions of frailty, 
but the two dominant ones are the Fried criteria, also known as the phenotype model 
(139), and the cumulative deficit model (140). The cumulative deficit model has been 
described as the “the more things individuals have wrong with them, the more likely 
they are to be frail” (141). The 5 Fried criteria describe a physical phenotype which 
includes weight loss, low grip strength, self-reported exhaustion, slow walking speed 
and low physical activity. If no criteria are present a person is described as robust, and 
if a person fulfils 3 or more criteria they are frail. Sarcopenia is considered the aspect 
of frailty related to physical performance and muscle mass (142). Benefits to 
classifying older adults by frailty status is to improve risk estimation, to target 
preventive actions, or as a model of public health (59, 143). Assessing frailty is 
becoming a routine part of treatment of older persons and is recommended by several 
disease specific guidelines, such as for colon cancer (144) heart failure (145) and 
aortic stenosis (146).  
 
Cachexia 
Cachexia is characterized by a rapid and substantial loss of lean muscle mass and is 
caused by specific diseases such as advanced cancer or late-stage organ failure. 
Sarcopenia and cachexia are distinct conditions, but frequently concurrent. In contrast 
to cachexia, sarcopenia is age-related, multifactorial and slowly progressive. Other 
features of cachexia are reduced strength, anorexia, fatigue and elevated inflammatory 




Malnutrition and sarcopenia frequently coexist and share many characteristics such as 
increased mortality, low albumin and low BMI (137, 148-150). Hemoglobin and 
serum albumin are biomarkers of malnutrition and are closely associated with muscle 
mass and physical performance (149). Figure 5 shows how sarcopenia can be related 
to malnutrition. The latest statement of the European Society for Clinical Nutrition and 
Metabolism on malnutrition recommends using low muscle mass, defined as fat free 
mass index of <15kg/m2 in women and <17kg/m2 in men, as one method for 
diagnosing malnutrition (151). Optimizing nutritional status has promise as treatment 
of sarcopenia (152). 
 
 




Sarcopenic obesity describes a phenotype where the person has a large body fat 
percentage, and a relatively low muscle mass component with low muscle strength and 
physical performance (153). Obese older persons develop greater impairments of 
activities of daily living compared to normal-weight persons (152, 153), and have 
greater risk of falls (154) and hip fracture (155). The FNIH sarcopenia project 
addresses sarcopenic obesity by recommending cut points for low muscle mass as 













many with sarcopenic obesity have a high BMI. Sarcopenic obesity complicates the 
assessment of sarcopenia status. Measuring muscle mass by anthropometry is less 
precise in persons with large amounts of subcutaneous adipose tissue (111). Some 
research suggest that intramuscular fat is stronger predictor of strength than muscle 
size (154). Intramuscular adipose tissue can only be assessed by CT or MRI. Muscle 
strength increases with increasing BMI, and the EWGSOP has recommendations for 
cut-points for low grip strength by category of BMI (73). 
 
1.2.5  Sarcopenia in clinical practice  
In predicting adverse outcomes 
Muscle mass, muscle strength and physical performance are interrelated and have 
different relationships to adverse outcomes. Muscle mass has a weak association with 
disability and mobility, but is associated with muscle strength (77), which in turn is a 
stronger predictor of adverse outcomes than muscle mass (77). Physical function, such 
as gait speed, predicts disability and death (129, 130). Sarcopenia is associated with 
developing reduced mobility, impairments in activities of daily living, increased rates 
of hospitalizations, fractures, becoming a resident of a nursing home and mortality 
(155). Sarcopenia is associated with falls (156, 157) and a possible explanation is a 
reduced ability to initiate explosive muscle contractions to regain balance (21). A 
systematic review and meta-analysis of prospective studies on sarcopenia by the 
EWGSOP criteria found an odds ratio of 3.6 for mortality in 11 studies and an odds 
ratio of 3.0 for functional decline in 6 studies (135).  
 
Prevention and treatment of sarcopenia 
The principal method of preventing sarcopenia is physical activity and exercise (158, 
159). Few interventional trials have used sarcopenia status as an endpoint (160). 
Several trials have targeted specific aspects of sarcopenia such as muscle function 
(159) or muscle mass (161, 162). Resistance training increases muscle mass and 
strength (162). Nutritional interventions have received much attention, especially in 
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the form of oral nutritional supplements with high protein content and vitamin D 
(163), or in combinations with exercise (164). The effects of different nutritional 
interventions have so far been limited (78, 164). For some patients, sarcopenia is 
caused by specific diseases. In those cases, the best treatment of sarcopenia is 
treatment of the underlying disease. Examples are medical treatment of heart failure 
(96) or liver transplantation for patients with end-stage liver disease (165). There is 
great interest in pharmacologic treatments of sarcopenia due to the potential to prevent 
functional impairment in aging populations and to reduce the need for 
institutionalization. Several drugs are undergoing clinical trials in humans, but none 
are currently approved for the treatment of sarcopenia. Intervention studies of 
testosterone treatment in older men with low testosterone showed no evidence of effect 
on walking distance (166), but improved bone mineral density (167). Selective 
androgen receptor modulators act on androgen receptors in selected tissues and aim to 
reduce the risk associated with unwanted androgen stimulation. Ghrelin is a hormone 
that stimulates appetite, increases growth hormone and insulin growth factor. Ghrelin 
agonists are undergoing trials in humans to treat cancer cachexia (168). Bimagrumab, 
a monoclonal antibody that is an inhibitor of myostatin, is currently undergoing trials 
as treatment of sarcopenia (169). ACE inhibitors have shown some promising results 
in improving physical performance (170). 
 
1.3 Sarcopenia in hip fracture patients 
Patients with hip fracture are of special interest in sarcopenia research (171). These 
patients have many of the characteristics associated with sarcopenia, including older 
age, female sex, malnutrition, falls and fractures, reduced mobility and impairments in 
in activities of daily living. In persons with sarcopenia the habitual force of skeletal 
muscle contractions on the skeleton is reduced which leads to weaker bone structure 
(172).Targeting sarcopenia is a potential mechanism for improving outcomes after hip 
fracture (173). Patients have lower grip strength and gait speed compared to controls 
(174). There are several studies on patients with hip fracture examining specific 
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aspects of the condition of sarcopenia, such as muscle mass, muscle strength or muscle 
function. There are fewer studies using the newer sarcopenia framework of examining 
both low muscle mass and reduced muscle function. The prevalence of sarcopenia in 
hip fracture patients was found to be 12-74% in men and 18-68% in women in 6 
studies using the newer definitions of sarcopenia (148, 173, 175-178). Progressive 
resistance exercise is the main treatment for improving physical performance in 
patients with hip fracture (38, 179). Nutritional interventions for improving muscle 
mass in hip fracture patients have been investigated in two recent studies of (177, 178), 
but with inconclusive results. Testosterone is of interest as treatment for sarcopenia in 
women with hip fracture, but a Cochrane review of three small intervention studies 
found insufficient evidence of effect (180). A non-steroidal selective androgen 
receptor modulator drug has announced promising results of a 12 week phase 2 study 
in 108 patients with hip fracture, but results have not undergone peer review (181). 
The myostatin inhibitor Bimagrumab is currently studied in hip fracture patients with 
results expected in 2018 (182).  
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2. Aims and hypothesis 
This thesis is based on the research project sarcopenia in patients with hip fracture. 
The aim of this thesis is to investigate sarcopenia as a clinically useful risk factor for 
adverse outcomes in patients with acute hip fracture. Determining sarcopenia status 
can aid in identifying vulnerable patients and contribute to personalized medicine. The 
results are presented in four papers. 
 
• In paper I, we aim to validate bedside measurement of muscle mass, which is 
necessary for determining sarcopenia status. Our hypothesis is that BIA and 
anthropometry are valid methods for measuring muscle mass in patients with 
hip fracture. 
• In paper II, our aim is to validate BIA for determining the body composition of 
patients with recent surgery and who have surgical implants. Our hypothesis is 
that BIA measurements are not affected by hip fracture and type of surgical 
implant. 
• In paper III, we aim to assess the relevance of sarcopenia in patients with hip 
fracture by investigating the feasibility of diagnosing sarcopenia at the bedside 
and the prevalence of sarcopenia. Our hypothesis is that it is feasible to 
determine sarcopenia, that it is a prevalent condition, and that it is associated 
with established risk factors for adverse outcomes. 
• In paper IV, our aim is to investigate sarcopenia as a risk factor for adverse 
outcomes after hip fracture. Our hypothesis is that sarcopenia status predicts 
change in mobility and other adverse outcomes in the year after fracture. 
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3. Methods  
Sarcopenia in patients with hip fracture is an observational, prospective, multicenter 
study on 282 acute hip fracture patients with one-year follow-up. Table 2 gives an 
overview of the 4 papers published on the findings of the study. These form the basis 
of this thesis. Papers I and II included patients from Haraldsplass Deaconess Hospital 
and Haukeland University Hospital, whereas papers III and IV also included 
participants from Diakonhjemmet Hospital. In paper I only those who returned for 
follow-up at three months were used for analysis, while paper II analyzed participants 
who were assessed in hospital or at follow-up. Papers III and IV used the whole 
sample of 282 participants. 
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Table 2: Overview of the four papers of this thesis 
Paper  N  Setting  Hypothesis  Principal findings 
I  162  3 months after hip 
fracture at HDS 
and HUS. 




 BIA and anthropometry can 
identify low muscle mass. 
II  203   Hospitalisation 
and 3-month 
follow-up at HDS 
and HUS. 
 BIA is not affected 
by surgical implants 
or surgery. 
 BIA is not affected by surgical 
implants but is affected by 
fracture and surgery. 
III  282   Hospitalisation at 
HDS, HUS and 
DS. 
 It is feasible to 
determine sarcopenia 
and sarcopenia is 
common. 
 Determining sarcopenia was 
feasible, prevalence was 37% 
and was associated with age, 
comorbidities and malnutrition. 
IV  282  One-year follow-
up at HDS, HUS 
and DS. 
 Sarcopenia predicts 
change in mobility 
after hip fracture. 
 Sarcopenia does not predict 
change in mobility, but reduced 
mobility, B-ADL and 
institutionalization or death. 
Table 2. N: number of participants. HDS: Haraldsplass Deaconess Hospital. 
HUS: Haukeland university hospital, DS: Diakonhjemmet hospital. BIA: 
Bioelectrical impedance analysis. B-ADL: Barthel activities of daily living 
 
3.1.2 Setting 
Participants were recruited when in hospital for surgical repair of hip fracture at 
Haraldsplass Deaconess Hospital, Haukeland University Hospital, Bergen, Norway, or 
Diakonhjemmet Hospital, Oslo, Norway during 2011-2013. Inclusion criteria were age 
65 years and older, able to walk without help from another person before the hip 
fracture, and able to give informed consent. Permanent residents of nursing homes or 
patients who had an expected life expectancy of less than three months were excluded. 
Participants with pacemakers or implanted defibrillators were excluded as BIA can 
interfere with implanted electrical devices. Bone disease, apart from osteoporosis or 
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osteomalacia, was also an exclusion criterion. Participants could not suffer from 
delirium, severe pain, have acute respiratory failure or be in shock at inclusion. 
 
3.1.3 Ethics 
All participation was by written, informed consent. Patients were included in the 
postoperative phase as pain and anxiety is reduced after surgery. Participants received 
information about the study and were asked to sign the consent form on a subsequent 
day. In situations where the capacity for consent was in doubt, experienced medical 
doctors and the rest of the team treating the patients were consulted. Institutional 
approval was granted from the participating hospitals, the National Hip Fracture 
Register and the Regional Committee on Medical and Health Research Ethics, REC 
South East with case number 2011/1322/REK. The study was conducted according to 
the principles of the Declaration of Helsinki (183). 
 
3.1.4 Data collection 
Patients admitted to hospital with suspected hip fracture were screened for inclusion 
when research staff was present. Some patients were discharged or refused further 
examinations before all data were collected. We did not record the details of the 
patients who did not participate in the study. The participants’ pre-fracture 
impairments in activities of daily living were determined by Barthel activities of daily 
living (B-ADL) (184). Nutritional risk was assessed with the nutritional risk screening 
(NRS 2002) (185). Serum albumin and 25-OH vitamin D were measured in the fasting 
state, either pre- or postoperatively. Comorbidities and the ASA score (186) were 
assessed by chart review, and the Charlson comorbidity index was calculated (187). 
Information on the number of medications used and any use of supplemental vitamin 
D was collected at discharge. Length of stay in hospital was collected from the 
electronic health record. Information on previous hip fracture, type of hip fracture and 
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surgery was made available from the National Hip Fracture Register. Vital status was 
supplied by the National Registry. 
 
3.1.5 Muscle mass 
Validating BIA and anthropometry for identifying low muscle mass in patients with 
hip fracture was the topic of paper 1. Table 3 lists the equations for determining ALM 
by BIA and anthropometry. 
 
Table 3. Appendicular lean mass equations by BIA and anthropometry 
First author  BIA equations 
 
Kyle (188) -4.211+(0.267×height2)/resistance + 0.095×weight+1.909×sex -0.012 × 
age+0.058 × reactance 
Tengvall (189) (-24.021+0.33×height-0.031×resistance+0.08 3×reactance -(1.58 +1.58×sex) + 
0.046×weight)/1.19+1.65 
Janssen (190) (height2/resistance×0.401+(sex×3.825) +(age×-0.071) +5.102)/1.19+1.65 






Villani (192) 22.28 –0.069×age+0.407×weight– 0.807×BMI–0.222×MAC  
Heymsfield 
(112) 
(height×0.0264+(0.0029 ×((MAC-πTSF)2/4π)- (10 for men, or 6.5 for 
women)))/1.19+1.65 
Table 3. Sex: Men=1, women=0. Height, centimeters. Weight, kg. BMI: body 
mass index, kg/m2. Resistance and reactance, Ohm. Age, years. MAC: 
midarm circumference, cm. TSF: triceps skinfold, cm. Height, cm.  
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Bioelectrical impedance analysis 
We studied the validity of BIA for determining body composition in patients with hip 
fracture in papers I and II. BIA measurements in hospital were performed when the 
patients had returned to the orthopedic ward after surgery. BIA was measured with the 
participant supine in a hospital bed by single frequency tetrapolar BIA devices, RJL 
quantum systems III (RJL systems, USA) and Body impedance analyzer BIA 101 ASE 
(Akern Srl, Italy). The resistance and reactance to a current of 0.4 or 0.425 
milliampere at a frequency of 50,000 hertz was determined. Electrodes (RJL systems, 
USA) were placed on the dorsum and wrist of the hand, and at the ankle and dorsum of 
the foot. Arms and legs were splayed and not in contact with other parts of the body. 
Rings, bracelets and wristwatches were removed, if possible. Patients were measured 
first on one half of the body, then immediately afterwards on the other half using a 
new set of electrodes, by the same operator and using the same BIA device. In total 
there were four BIA measurements per participant, two measurements per participant 
in hospital and two at follow-up at three months. Participants were not fasting, and 
they did not empty their bladder before measurements. All BIA measurements were 
done by research staff. The decision to measure both sides of the body was by protocol 
amendment after inclusion had started. For paper I, BIA values were used in equations 
by Kyle et al (189), Tengvall et al (189), Janssen et al (191) and Sergi et al (191) for 
predicting muscle mass. See table 3. Results for total body muscle mass by the 
Tengvall and Janssen equations were converted to ALM by model 1 described by Kim 
et al (106), taking into consideration intramuscular adipose tissue. Participants at 
Diakonhjemmet hospital were measured with a different type of BIA device which 
was not comparable to the BIA devices used in Bergen, and were not analyzed. 
 
Anthropometry 
Validation of anthropometry to determine muscle mass was a topic of paper I. 
Anthropometry was used for diagnosing sarcopenia in paper III and IV. Participants 
were weighed with light clothes, without shoes. Height was primarily determined 
using a wall mounted stadiometer. Some of the patients were not able to have their 
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standing height measured. In these cases, self-reported height or body length measured 
from heel to crown while lying in bed was measured. If height at baseline was still 
missing, height measured at follow-up was used. Triceps skinfold and midarm 
circumference was measured by trained staff. Midarm circumference was measured on 
the right arm at the mid-point between the acromion and olecranon process with the 
arm hanging down. Triceps skinfold was measured using a skinfold caliper 
(Harpenden, Baty International, Great Britain). Measurements of triceps skinfold were 
repeated until two readings were within 1mm. BMI was calculated. Total body muscle 
mass by anthropometry Heymsfield was converted to ALM (106). 
 
Dual-energy X-ray absorptiometry  
Whole body DXA was the reference method for determining ALM in paper I. 
Measurements were performed by experienced technicians using one single 
densitometer (Lunar Prodigy, GE, USA, encore version 13) at an outpatient clinic. The 
densitometer was calibrated every day and was stable during the measurement period. 
The in vivo short-term precision for lean mass was <1%. Participants at 
Diakonhjemmet hospital did not undergo whole body DXA. 
 
3.1.6 Sarcopenia status 
Sarcopenia status was determined postoperatively, at follow-up at three months, and 
was analyzed in papers III and IV. We used the definition of sarcopenia recommend 
by the EWGSOP (73), but with two important modifications. We used anthropometry 
to determine low muscle mass, which is not recommended by the EWGSOP for 
research purposes. Further, for sarcopenia status we used the two categories of not 
sarcopenia and sarcopenia, instead of the four categories of normal, presarcopenia, 
sarcopenia and severe sarcopenia. To be categorized as sarcopenic participants had to 
have low muscle mass and one of either low grip strength or low mobility. Total body 
muscle mass was estimated by anthropometry by the method of Heymsfield et al (112) 
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and converted to ALM by model 1 of Kim et al for paper III (106) and model 1 by 
Kim et al for paper IV (107). The difference between the two models was that 
intramuscular adipose tissue, set at 0.64kg, was subtracted from ALM for paper IV, 
but not for paper III. Cut-points for low muscle mass were ALM divided by height 




Grip strength was measured with a Jamar dynamometer (Lafayette Instrument, USA). 
One side was measured three times and immediately afterwards the other side. Grip 
strength was measured while participants were sitting upright in bed or on a chair. The 
elbow was flexed with the shoulder and wrist in the neutral position. We accepted a 
reading of zero if the patient attempted to perform the measurement and followed all 
aspects of the instruction. There was a brief interval between attempts while the 
dynamometer was repositioned. The single best value was used. The cut-points for low 
grip strength was ≤30kg for men and ≤20kg for women, as recommended by the 
EWGSOP (73). 
 
The New Mobility Score 
Mobility was determined by the New Mobility Score (NMS). The NMS assesses 
mobility before the fracture by interview. It ranges 0-9; a score of zero indicates that 
the person is not ambulatory and nine indicates an ability to walk without assistance 
while shopping (193). See table 4. Low mobility was defined as NMS <5, based on the 
cut-point recommended for predicting mortality after hip fracture (194). The NMS is 
recommended by AOTrauma and Danish national guidelines for treatment of hip 
fractures to determine the pre-fracture mobility (195, 196). 
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 Table 4. The New Mobility Score. 
 Able to do 
without 
difficulty 
 On their 
own, but 
with an aid 
 Only with 
someone’s 
help 
 Not at all, i.e. 
bed, chair or 
homebound 
Can the patient do 
their own shopping? 
3  2  1  0 
Is the patient able to 
get out of the house? 
3  2  1  0 
Is the patient able to 
get about the house? 
3  2  1  0 
Table 4: The New Mobility Score, adapted from Parker and Palmer (194). 
The three categories are added to create a score 0-9. 
 
Follow-up at three months 
Follow-up at three months was at outpatient clinics. Scheduling of the follow-up 
appointment was flexible to increase attendance and minimize the inconvenience for 
participants. Measurements of body composition with DXA, BIA and anthropometry 
were performed on the same day. Investigators were blind to the results for ALM for 
the different measurements. Sarcopenia status and B-ADL was determined. Follow-up 
data at three months were used in paper I, II and IV. 
 
Outcomes at one-year 
Outcomes after one year of follow-up were described in paper IV. We did a telephone 
interview with patients or their care-giver. Telephone interview was chosen to reduce 
the efforts and costs of acquiring the information for both study investigators and 
participants. Information on reoperations or second hip fractures was supplied by The 
Norwegian Hip Fracture Register (46). We collected information on NMS, B-ADL, 
hospitalizations, reoperation for hip fracture, new fractures, new hip fractures, and 
becoming a resident of a nursing home. The primary outcome in paper IV was change 
in mobility, calculated as NMS at one year minus the pre-fracture NMS.  
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3.1.7 Statistical analyses  
A range of different statistical analyses were used in the thesis. Participant 
characteristics were described with mean values and standard deviation, median values 
and interquartile range, or counts with percentages. Several versions of IBM SPSS 
Statistics for Windows (IBM Corp., Armonk, NY, USA), Stata Statistical Software 
(College Station, TX, USA) and one version of R, 3.3.0 (R foundation for statistical 
computing, Vienna, Austria) (197) were used for statistical analysis. All analyzes were 
two-sided and p≤0.05 was considered significant. 
 
Statistics in paper I  
For the four different BIA methods and the two anthropometric methods participants 
were classified as having low or normal ALM and compared to low or normal ALM 
by DXA using receiver operating characteristics with area under the curve (AUC) 
(198). Low ALM was defined as ≤7.25 kg/m2 for men and ≤5.67 kg/m2. The 
ROCGOLD function in STATA was used to compare the AUC of the different 
methods. Analysis was stratified by sex and corrected for multiple testing. Sensitivity 
and specificity for identifying low muscle mass was presented graphically and positive 
and negative likelihood ratios for each method was determined. ALM by the different 
methods was analyzed as a continuous variable compared to ALM by DXA by the 
method of Bland and Altman with mean bias and limit of agreement (LOA) (199). For 
use in individual patients we decided that the method should be able to identify ALM 
with a precision within 1kg of that determined by DXA, as a 1kg change in muscle 
mass is considered clinically relevant (164). For analysis of groups of patients, the 
mean bias should be as small as possible. 
 
Statistics in paper II 
The resistance of the fractured and unfractured hip was analyzed by mean bias with 
LOA according to the method of Bland and Altman (199). This method was chosen 
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because we considered the measurements of the fractured and the unfractured side of 
the body as two alternative methods for determining whole-body muscle mass. We 
assumed that BIA measurements on the side of the unfractured hip were not affected by 
the surgery or surgical implants of the fractured hip. We also assumed that any effect of 
fracture or surgery would be reduced at follow-up compared to while in hospital. 
Resistance and reactance of the fractured side was compared with unfractured side using 
paired T-test, in hospital and at follow-up. For determining the influence of surgical 
implants on resistance and reactance, the difference between the resistance and 
reactance of the fractured and unfractured hip was analyzed by analysis of variance 
using three categories of surgical implant, hip screws, compression hip screw and hip 
arthroplasty. 
  
Statistics in paper III 
To determine the feasibility of assessing sarcopenia status we described our problems 
with gathering data. The association between sarcopenia as dependent variable and the 
different risk factors as independent variables was analyzed in separate logistic 
regression analyses with odds ratios and 95% confidence intervals. Analysis was 
adjusted for age, BMI and sex as predictor variables. Separate analysis was also 
performed with low muscle mass, low grip strength and low mobility as dependent 
variables. 
 
Statistics in paper IV  
Our primary hypothesis was that sarcopenia status predicted change in NMS as a 
continuous variable. We also analyzed change in B-ADL. For these analyses we used 
regression analyses with NMS and B-ADL as dependent variables and sarcopenia 
status at baseline and age, sex and BMI as predictors. The relationship with age and 
BMI was modelled with restricted cubic splines with 3 knots, placed at the 10%, 50% 
and 90% quantiles. For the regression analyses, missing values were imputed using 
multiple imputation. Based on clinical experience we assumed that a change in NMS 
of 1 point was clinically significant. In secondary analysis we examined the 
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association between sarcopenia status and NMS and B-ADL using the same method. 
For the association between sarcopenia and new clinical fractures, new hip fracture, 
reoperations, all-cause hospitalization, becoming a resident of a nursing home, and the 
combined endpoint of nursing home or death we used Fisher’s exact test. We also 
explored the association between the separate components of sarcopenia (muscle mass, 
grip strength and mobility) with change in mobility and change in B-ADL. The 
associations were analyzed using regression analysis with muscle mass, grip strength 
and mobility as continuous variables. 
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4.  Results 
This thesis has investigated sarcopenia in a population of community-living, 
ambulatory and cognitively intact patients with acute hip fractures. We have found that 
anthropometry and BIA have a moderate ability to identifying patients with low 
muscle mass. BIA is affected by recent surgery, but not by surgical implants. It is 
feasible to determine sarcopenia status in acute hip fracture patients and the prevalence 
of sarcopenia is 37%. Sarcopenia is not associated with change in mobility from 
prefracture to one year after fracture, but it is associated with impairments in mobility 
and activities of daily living, institutionalization and mortality. 
 
4.1 Paper I: Identifying patients with low muscle mass 
In paper I we showed that bedside methods for determining muscle mass in hip 
fracture patients have moderate accuracy in identifying a state of low muscle mass. 
Anthropometry by the Heymsfield method had an AUC of 0.71 in women and 0.64 in 
men for correctly identifying low muscle mass, and 70% in women and 69% of men 
participants were correctly classified. The different BIA methods had AUCs ranging 
0.66-0.89. The method of determining ALM by anthropometry by Villani et al had 
poor discriminatory ability with a 95% CI of the AUC which included 0.50, indicating 
that the method was no more accurate than chance. The magnitude of the LOA when 
comparing ALM by the different BIA methods ranged 6.0 to 8.3kg in women and 6.9 
to 9.4kg in men. The magnitude of the LOA for comparing ALM by anthropometry 
was 7.6 to 10.2kg in women and 11.5 and 14.5kg in men. The mean ALM of the 
participants was 14.8kg in women and 20.8kg in men and it is obvious that the 
precision is insufficient for use in individuals. Mean bias was low for all the different 
methods in women, ranging -1.8 to -0.8kg, indicating that the methods were suitable 
for use at a group level. Mean bias varied greatly by the different BIA methods in men, 
ranging from -4.7 to -0.7 kg. Mean bias by anthropometry in men was low at -0.6kg by 
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anthropometry Heymsfield and 0.1 by anthropometry Villani. BIA and anthropometry 
had acceptable precision in assessing ALM in groups. 
 
4.2 Paper II: Influence of fracture and surgical implants on 
BIA measurements 
This paper aimed to answer two questions about the use of BIA in hip fracture 
patients: 1. Does hip fracture and surgery affect BIA readings? 2. Does surgical 
implants affect BIA readings? We found a small but statistically and clinically relevant 
effect of fracture and surgery on resistance on the side of the hip fracture shortly after 
the fracture. Our proposed solution is to measure the opposite side of the body to the 
fracture. We found no effect on BIA measurements by the presence of cannulated 
screws, arthroplasty or dynamic hip screws. BIA can be used in acute hip fracture 
patients if the side opposite to the fracture is measured and BIA readings are not 
affected by commonly used surgical implants of the hip.  
 
4.3 Paper III: Feasability of determining sarcopenia and 
prevalence of sarcopenia 
In paper III, we determined sarcopenia status in 202 out of 282 participants and found 
that it is feasible to determine sarcopenia status in acute hip fracture patients using 
anthropometry, grip strength and NMS. We determined sarcopenia status a median of 
4 days after surgery. An important source of missing values for sarcopenia status were 
difficulties in determining height. Prevalence of sarcopenia was 37% and sarcopenia 
was associated with increasing age, lower BMI, lower serum albumin, using a greater 
number of medications and a higher ASA score. There were no differences in rates of 
sarcopenia by sex, but men had a greater prevalence of sex-specific low muscle mass. 
The findings support the feasibility of determining sarcopenia among patients with hip 
fracture who were living in the community and are independently mobile before the 
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fracture. The prevalence of sarcopenia of 37% supports sarcopenia as a relevant risk 
factor in the population of acute hip fracture patients. 
 
4.4 Paper IV: Sarcopenia status and outcomes at one year 
In paper IV we found that having sarcopenia did not predict change in mobility from 
pre-fracture until one year after hip fracture, or from pre-fracture until three months, or 
from three months until one year. Sarcopenia was associated with having reduced 
mobility and more impairments in B-ADL one year after hip fracture with a NMS 5.8 
and B-ADL 16.8 among those with sarcopenia at baseline, and NMS 6.8 and B-ADL 
18.6 in those without sarcopenia. Having sarcopenia at baseline was associated with a 
higher likelihood of becoming resident of a nursing home with an odds ratio 3.2 and an 
odds ratio of 3.6 for the combined endpoint of death or becoming a resident of a 
nursing home. We recommend that pre-fracture mobility be determined in all hip 




The purpose of the thesis has been to investigate sarcopenia as a clinically useful risk 
factor in hip fracture patients. This was done in three steps. The first step was to 
investigate the validity of bedside methods for determining muscle mass. We have 
described this this in papers I and II. Secondly, we investigated the feasibility of 
determining sarcopenia in postoperative patients and the prevalence of sarcopenia. 
These results were presented in paper III. Building on our results from the findings in 
the previous two steps enabled us to investigate how sarcopenia predicted change in 
mobility and was associated with outcomes at one year. 
 
5.1 Relevance of sarcopenia in hip fracture patients 
Hip fractures, with their great prevalence and large influence on health, are a relevant 
topic for research. The treatment of hip fracture has improved since 2005 (56), and it is 
reasonable to assume that further improvement is possible considering that 
orthogeriatric care and extended physical rehabilitation are not yet routine part of 
treatment. Many patients with hip fracture suffer from reduced muscle mass and reduced 
physical function (17, 148, 175, 200). Sarcopenia is a modifiable risk factor that can be 
prevented and treated with exercise interventions (201). The relevance of sarcopenia 
status in hip fracture patients is determined by the prevalence of sarcopenia, that it can 
be diagnosed at the bedside, that it predicts adverse outcomes, and that targeting 
sarcopenia improves health. This thesis has shown that sarcopenia is a relevant risk 
factor for adverse outcomes, but it is not known if treating sarcopenia will improve 
health. Extended rehabilitation is expensive in terms of time, manpower, and motivation. 
It is reasonable to assume that identifying a group of patients with increased risk of 
adverse outcomes, such as patients with sarcopenia, can enable better use of resources 




5.2.1 Study design 
The aim of this thesis was to investigate sarcopenia in patients with hip fracture and 
for this purpose an observational study design was the best option. When we planned 
the study in 2011 there was little information on sarcopenia in hip fracture patients in 
the published literature, and no information on the feasibility of determining 
sarcopenia, the validity of the different methods to determine sarcopenia, prevalence 
of sarcopenia and the association of sarcopenia with outcomes. A case control study, 
where older persons without hip fracture were assessed for sarcopenia, would have 
enabled more robust conclusions regarding the prevalence of sarcopenia, but was not 
possible due to resource constraints. 
 
We decided on a multicenter study design to increase generalizability of the results by 
reducing the influence of local factors, increase the number of included patients and to 
increase statistical power to analyze our hypotheses. Further, we aimed to develop ties 
to other centers treating patients with hip fracture for future collaboration. Inclusion of 
participants at three hospitals led to less central control of the conduct of the study, and 
to greater rates of missing values, lower rates of recruitments and loss of information 
on the patients screened for inclusion but not included. To counteract this loss of 
control we could have compensated with closer follow-up at each hospital with weekly 
visits and greater use of research nurses, but we did not have the necessary resources 
available. 
 
We chose follow-up at three months on the assumption that most of the participants 
would have returned to their own homes and had regained sufficient mobility to attend 
at that time. Follow-up at one-year was chosen as tradeoff between participants 
regaining most of the lost mobility after hip fracture, and to minimize missing values 
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due to death and withdrawals. The rate of death is greatest in the weeks after hip 
fracture (25), whereas mobility plateaus at one year (36).  
 
5.2.2 Population 
Generalizability of results is a major concern of any study. Our study had wide 
inclusion criteria and recruited participants at three centers. We included only 
participants able to give informed consent, partly because we found it ethically 
challenging to recruit patients for a study where there were few benefits for the 
participants. We included patients older than 65 years to focus on the older population. 
There is reason to believe that younger patients are different from older patients, with 
a greater prevalence single disease effects leading to falls and fractures. We chose not 
to include residents of nursing homes. Older persons living in nursing homes in 
Norway have a prevalence of dementia of more than 80% (202) and would generally 
not have the capacity for consent. They would also have more difficulties in attending 
follow-up examinations. Some research indicates that patients without the capacity for 
consent receive less benefit from rehabilitation interventions (62). 
 
We included only a minority of all the patients who were operated on for hip fracture 
at the participating hospitals during the period of inclusion. The number of patients 
with hip fracture operated on during the period of inclusion was 1,592, of which 282 
were included. This is a major limitation of our study and reduces the generalizability 
of our results. It would have been useful with more information about the participants 
who weren’t eligible or did not consent to participation, but we failed to record this 
information. The Regional Committee on Medical and Health Research Ethics 
requested that participants be given information on the first day and to sign the consent 
on a subsequent day. The extra time was deemed necessary for the patients to consider 
whether to participate. This unusual process of obtaining consent probably reduced the 
number of patients included. Some patients were discharged home before the process 
was completed, and some patients were never screened for inclusion because research 
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staff were absent from the wards. Even taking these limitations into consideration, the 
included population was old, suffered from mobility impairments, impairments in 
activities of daily living, were frequently hospitalized, became institutionalized, 
experienced fractures, reoperations and mortality during the follow-up. When we 
compare the age and ASA score of the participants in the present study with all 
patients in the Norwegian National Hip Fracture Register we find similar values. Age 
was 79 years in the study and 80 years in the register, ASA score was 2.5 in the study 
and 2.7 in the register (26). The sample size of 282 participants compares favorably to 
the other current studies on sarcopenia in patients with hip fracture. See table 5 for an 
overview of recent studies. For paper I we included 162 patients of which 43 men were 
available for analysis stratified by sex. When comparing 5 different methods for 
identifying low muscle mass a sample of 43 men was insufficient to reach firm 
conclusions. We believe the results of this thesis are valid for older hip fracture 
patients living in their own home, able to walk without assistance and without 
cognitive impairment. 
 
5.2.3 Papers I and II: validating bedside methods for determining 
muscle mass 
The topic for papers I and II was validating bedside measures of body composition. 
We were unable to measure participants by DXA during hospitalization for several 
reasons: patients were relatively immobile, Haraldsplass Deaconess Hospital did not 
have a DXA machine, the DXA machine at Haukeland University Hospital was in a 
separate building from the orthopaedic ward and the treating clinicians were worried 
that trying to measure body composition by DXA might lead to delays in discharge 
from hospital. The DXA machine at Haukeland University Hospital was a Lunar 
Prodigy whereas it was a Hologic Discovery at Diakonhjemmet Hospital, and DXA 
machines from different manufacturers are poorly cross-validated. MRI or CT would 
have been more precise in determining ALM and would also enable assessment 
intramuscular adipose tissue but were not available due to cost and the effort 
demanded of the participants. We decided not to use the equation by Lee et al for 
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determining muscle mass. The Lee equation is based on height, weight, sex, race and 
age and we were interested in estimates of muscle mass that could measure change in 
muscle mass beyond measuring change in weight (113). The Heymsfield method for 
determining total body skeletal muscle had the disadvantage that it was necessary to 
measure triceps skinfold, which is considered technically difficult (112). An advantage 
of the Heymsfield method is that it is independent of weight and age. We found that 
BIA or anthropometry have insufficient precision to determine muscle mass as a 
continuous variable at the individual level, as evidenced by the wide LOA by the 
Bland-Altman analyses. This indicates that anthropometry and BIA are unable to 
determine precise ALM, to monitor changes in ALM in interventions studies or during 
rehabilitation. We did find an acceptable ability to identify low ALM with the different 
BIA methods with AUC ranging 0.66-0.89 for the different prediction equations and 
an AUC of 0.64 for women and 0.72 for men for anthropometry Heymsfield. We did 
not have sufficient statistical power to determine the single best method to identify low 
muscle mass due to the limited number of participants, because analysis was stratified 
by sex and due to correcting for multiple testing. It was necessary to stratify by sex 
because men are substantially different from women. They have greater muscle mass, 
are younger and suffer higher rates of adverse outcomes compared to women. 
Correction for multiple testing was necessary since we compared 6 different methods, 
but an option would have been to investigate fewer methods. 
 
The aim of paper II was to examine the validity of BIA in acute hip fracture patients 
by investigating the effect of surgery and surgical implants on BIA measurements. We 
decided to analyze the effect of surgical implants on BIA measurements by dividing 
the surgical implants into three categories based on the mass of the implant and their 
position in relation to muscle and bone. The categories were cannulated screws, 
compression hip screws and hip arthroplasty. We presented the individual data points 
in scatterplots to more clearly show the distribution of measurements including 
outliers and the return to the mean from baseline to follow-up. We could possibly have 
increased the precision of the BIA analysis by having the participants fasting, resting 
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in bed for 5 minutes before testing, having empty bladders and ensuring euvolemia. 
We believe that our results are valid and robust to potential inaccuracies in BIA 
measurements, since we used each person’s unfractured hip as control. We also 
consider our approach to performing BIA measurements a good balance between 
being feasible in clinical practice and adhering to recommendations for optimal 
measurements. 
 
5.2.4 Papers III and IV: Sarcopenia in patients with hip fracture  
The aims of papers III and IV were to determine the feasibility of determining 
sarcopenia in acute hip fracture patients and investigate the relevance of sarcopenia as 
a risk factor. We determined sarcopenia status in 202 of 282 participants. It was 
challenging to determine height and weight of the participants, as other studies on 
patients with hip fracture have found (30). For 52 participants with missing values for 
height determined during the hospital stay, we used height determined at follow-up. 
Determining height is necessary for identifying low muscle mass and diagnosing 
sarcopenia. Other studies on sarcopenia in patients with acute hip fracture have used 
supine height (177, 178), the length of the ulnar bone (148) and knee height (203) to 
estimate standing height. We reduced the problem of assessing height by using 
alternative methods, primarily self-reported height or supine height. 
 
We had high rates of missing values in the study. To gather as much information as 
possible about the participants, and to reduce the number of missing values we had a 
clear sequence and priority for the data collection. First; consent to participate, second; 
information about pre-fracture mobility, third; muscle mass by BIA and 
anthropometry, fourth; grip strength, and finally, all other variables. For the follow-up 
examination at three months we aimed to increase the attendance rate by being flexible 
in scheduling. In paper IV, we used multiple imputation in cases with missing values 
for the variables used in regression analysis. Imputation of missing values improved 
the validity of our analysis and generalizability of the results compared to using only 
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complete cases. Analysis limited to complete cases reduces statistical power, 
especially in multivariable analysis. Complete case analysis, also known as listwise 
deletion, limits the results of analysis to the part of the population without missing 
values, or requires that missing values are missing completely at random. An 
assumption of imputation of missing values is that missing values can be estimated by 
the pattern of missing values or other information in the dataset. Our results were 
similar in complete case analysis and when analysed with imputation of missing 
values, which indicates that our results were robust to the assumptions of both. This 
supports our findings of no effect of sarcopenia on change in NMS and B-ADL. 
 
Considerations regarding the diagnosis of sarcopenia 
There is no established consensus for diagnosing sarcopenia. We had to consider a 
broad range of options when deciding on how to define sarcopenia. For this research 
project we decided on the EWGSOP definition based on the authority of the group, 
and because it broadened the criteria for sarcopenia to include muscle strength and 
function in addition to muscle mass. The EWGSOP recommends several alternative 
definitions of low muscle mass such as muscle mass normalized for body weight or 
body weight and with different cut-points for low muscle mass (77). Muscle mass 
adjusted for body weight has been criticized for disproportionately classifying obese 
patients as sarcopenic, which is at odds with the beneficial effects of obesity on 
mortality in older persons (204). The FNIH sarcopenia project recommendations of 
ALM/BMI were not published at the time we wrote the protocol, and the changes did 
not seem sufficiently substantial to warrant a change in protocol.The different 
recommended cut-points for low muscle mass by the EWGSOP normalized for height 
squared were similar, ranging from 5.5kg/m2 to 5.67kg/m2 for women and 7.23 to 7.26 
kg/m2 for men, and for practical purpose the differences were small (73).  
 
The EWGSOP recommends using four categories of sarcopenia, normal, 
presarcopenia, sarcopenia, and severe sarcopenia. We decided against using the four 
categories because we were uncertain about the added value of including a 
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presarcopenia category. Di Monaco et al found that the group with presarcopenia had 
better outcomes for improvement in the B-ADL, compared to the group categorized as 
normal (176). One possible explanation is that grip strength is a stronger indicator of 
adverse outcomes than muscle mass and that the patients with presarcopenia, by 
definition, have normal grip strength. Using two categories increased our sample size, 
and is the approach most commonly used in studies on sarcopenia (148, 205). The 
EWGSOP does not recommend anthropometry for determining muscle mass in 
research, but it is well established in clinical practice. DXA was not an option for 
determining ALM in this study. We did not have financing for whole body DXA at 
Diakonhjemmet Hospital, and we did not believe that patients who had recently 
undergone surgery would be able to undergo DXA due to pain and immobility. We 
chose anthropometry for identifying low muscle mass because our results in paper I 
indicated that anthropometry had an acceptable discriminatory ability, and because this 
enabled us to determine sarcopenia status using the same techniques at all three 
hospitals. BIA was not available at Diakonhjemmet hospital. There are quick 
screening tools for sarcopenia (206), which could facilitate identifying acute hip 
fracture patients with sarcopenia. Goodman et al have developed a screening tool 
using age, sex and BMI to identify persons at risk of having low muscle mass (207) 
and Malmstrom et al have developed the SARC-F to identify patients with sarcopenia 
(208). The SARC-F was not published until after enrolment was finished, and so was 
not an option for us. 
 
We decided to use grip strength to determine low muscle strength, as this is the most 
widely used and studied measure of muscle strength. There are many different 
protocols for how maximal grip strength should be determined (110) and these 
differences in protocol can be clinically relevant (209). The Southampton protocol 
aims to standardize test conditions for grip strength (127). We adhered to most of the 
recommendations, with two exceptions. We accepted measurements while the patient 
was in bed instead of in a chair and we did not alternate hands for each attempt. We 
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encountered no difficulties in measuring grip strength, and consider it a useful tool in 
determining strength at the bedside. 
 
We chose the NMS as our measure of physical performance because we assumed that 
many of the participants would be unable to perform objective tests of physical 
performance, and to reduce the burden of participation of participants and 
investigators. The NMS is not one of the alternatives recommended by the EWGSOP, 
and the FNIH sarcopenia project only requires grip strength and muscle mass. Options 
recommended by the EWGSOP are all objectively measured tests of physical 
performance such as the Short Physical Performance Battery, usual gait speed, Timed 
get-up-and-go test and stair climb power test (73). Other studies on hip fracture 
patients where sarcopenia status is determined shortly after fracture, have not 
measured physical performance (200). A group of experts sponsored by the 
AOTrauma network recommends measuring the NMS at pre-fracture, at 90 days and 
at one-year (195). No studies have recommended a cut-point for low NMS in the 
context of sarcopenia, but NMS<5 indicates increased mortality risk (194). A pre-
fracture NMS<6 was associated with objectively measured physical function before 
discharge from hospital (210), having a reduced mobility at 6 months, or needing 
assistance in activities of daily living (211). The NMS has been used as an endpoint 
and repeated measure in intervention trials (212). It has a high interrater reliability 
(213). We found the NMS intuitive, easy to administer, acceptable for use by both 
investigators and patients, and easy to administer both for face-to-face and by phone 
interviews. There was a ceiling effect with more than half of our participants scoring 
the maximal NMS 9 before the fracture and we found the NMS to be a suboptimal tool 
for measuring rehabilitation because of the distribution of the scores (214). It is 
possible that alternative measurement scales developed for hospitalized older patients 
such as the cumulated ambulation score (215) or the de Morton Mobility index (216) 




We determined if participants were very ill during examination and if so 
measurements were postponed until patients recovered. It would have been 
informative if we recorded vital signs such as alertness, respiratory rate, pulse, blood 
pressure and temperature in order to assess the feasibility of determining sarcopenia in 
medically unstable patients, and how assessment of grip strength is changed in 
situations with abnormal vital signs. 
 
Sarcopenia is a predictor of falls (157). A detailed assessment of falls among our 
participants would have been useful and we could have contributed to insights into the 
relationship between sarcopenia and risk of falling in a high-risk population. We 
decided against recording falls as studies have shown that close follow up is necessary 
for accurate fall surveillance (217). We aimed to determine pre-fracture cognitive 
status with the IQCODE (218), but had trouble collecting the information from the 
next of kin, and were unable to use cognitive status in analysis. Smoking and harmful 
patterns of alcohol intake are associated with sarcopenia and hip fracture (86, 219-
222). We did not consider smoking or alcohol use as predictors of sarcopenia or 
mobility but would want to consider it in a future study. Excess rates of smoking and 
harmful alcohol intake are possible explanations for why male hip fracture patients 
have worse outcomes compared to female. 
 
We did not estimate the effect of sarcopenia on length of hospital stay since we 
consider this an outcome that is sensitive to confounding and that has an unclear 
relationship to sarcopenia. Most of the participants in our study were discharged to 
skilled nursing homes for rehabilitation lasting 2-4 weeks before being discharged to 
their own home. The median length of hospital stay was 6 days for those without 
sarcopenia and 7.5 days for those with sarcopenia. A small minority of participants 
were discharged to their own home, and some were discharged to hospital-based 
rehabilitation facilities. Short and long hospital stays can indicate both successful and 
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failed rehabilitation. We did not investigate the relationship between intensity of 
rehabilitation and outcome, which is a potential confounder of the relationship 
between sarcopenia and outcomes. 
 
5.3 Comparison with other studies 
5.3.1 Bedside methods for determining muscle mass in patients 
with hip fracture 
Villani et al investigated anthropometric assessment of total body muscle mass using 
anthropometry by the Heymsfield method with DXA as the reference method 2 weeks, 
6 months and 12 months after hip fracture (192). They found a poor precision with a 
magnitude of the LOA of 24kg at 2 weeks, 12kg at 6 months and 13kg at one year. 
The magnitude of the LOA found by Villani et al was comparable to what we found, at 
10kg for women and 15kg in men. Villani et al did not investigate the ability of 
anthropometry to identify low muscle mass and did not stratify his analysis by sex. In 
a subsequent paper Villani et al proposed a different equation for ALM by 
anthropometry, using a development and a validation cohort of patients with hip 
fracture (203). They found a magnitude of the LOA of 10 kg in the validation cohort. 
We investigated the precision of this equation in paper I and found a LOA of 8kg in 
women and 11.5kg in men, which is a comparable result. We conclude that our results 
for the precision of anthropometry in determining muscle mass in patients with hip 
fracture are comparable to the two Australian studies. 
 
We are not aware of any study on single frequency BIA to determine muscle mass in 
patients with hip fracture, but one study by Villani et al using multifrequency BIA 
(192). In a study on single frequency BIA compared to DXA in hospitalized older 
persons with a range of illnesses, the magnitude of the LOA of BIA compared to DXA 
for total body muscle mass was 7kg for BIA Tengvall, 6kg for BIA Kyle and 9kg for 
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BIA Janssen. Outliers corresponding to 7% of the participants were removed from the 
dataset (223). The results were of a comparable precision to what we found in our 
study where the magnitude of the LOA ranged 6-10kg for ALM. In general, results 
from the research describing the development of BIA derived prediction equations for 
ALM has greater precision than subsequent validation studies. We conclude that our 
results on the validity of BIA to determine muscle mass are in line with other research, 
with the caveat that we are not aware of any studies validating BIA or anthropometry 
to identify low muscle mass as a dichotomous outcome. 
 
The results from paper II are original and difficult to compare to previous research as 
our approach of using one half of the body as the control of the other side has not been 
investigated before. We have not identified previous research on the influence of 
fracture or surgical implants on BIA readings. 
 
5.3.2 Other studies on sarcopenia in patients with hip fracture 
We are aware of 6 previous studies on patients with hip fracture using both low muscle 
mass and low muscle strength or muscle function to diagnose sarcopenia (148, 173, 
175-178). The studies were heterogeneous in setting, methods used, and outcomes 
investigated. Some of the details of the studies are summarized in table 5. Patients 
were included during the acute hospital stay in 2 studies, during in-hospital 
rehabilitation in one study, and during post-acute rehabilitation in 3 studies. Patients 
had their sarcopenia status determined preoperatively in the study by Gonzalez-
Montalvo et al, and postoperatively ranging from a week to up to 52 days after the 
fracture in the other 5 studies. Sample size varied from 79 to 479 with a follow-up 
period varying from discharge from hospital to 12 months. Two studies, by Flodin et al 
and Malafarina et al, were intervention studies examining the effect of nutritional 
supplements on muscle mass, whereas the other studies were observational. 
Determination of muscle mass was by DXA in 4 studies and BIA in 2 studies, and all 6 
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studies used different cut-points for low muscle mass. The studies using BIA to 
determine muscle mass measured the unfractured side, and thus avoided the problem 
of the influence of the fracture on BIA measurements. All 6 studies used grip strength 
to determine strength, but with 4 different cut-points for low grip strength. Only the 
study by Malafarina et al measured of physical function (178). 
 
The prevalence of sarcopenia varied from 17% to 72%. Prevalence of presarcopenia in 
two studies varied from 12% to 21% (175, 176). Flodin et al found that the prevalence 
of sarcopenia increased from 24% in hospital to 29% one year after the hip fracture 
(177). Reporting of the association between sarcopenia, key demographics and risk 
factors was inconsistent across studies. Landi et al and Gonzalez-Montalvo et al 
reported an increasing prevalence of sarcopenia with age. Ho et al and Landi et al 
found a higher prevalence of sarcopenia in men compared to women, whereas 
Gonzalez-Montalvo et al found no association. Di Monaco et al included only women. 
 
Sarcopenia was associated with low BMI in three studies, there was no association in 
the fourth, while two studies did not report results. There was no association between 
malnutrition and sarcopenia in the studies by Landi et al and in Gonzalez-Montalvo et 
al when using serum albumin, vitamin D and the Mini Nutritional Assessment. The 
relationship between sarcopenia and comorbidities varied by study and how 
comorbidities were assessed. Di Monaco et al found no association between 
sarcopenia and number of concomitant diseases or number of medications. Gonzalez-
Montalvo et al found no association between sarcopenia and ASA score. Landi found 
an association between sarcopenia and increasing comorbidities using the Charlson 
comorbidity index, but not for number of medications. The association between 
sarcopenia and activities of daily living before the hip fracture was assessed in three 
studies, and no difference was found. Landi et al found a greater improvement in B-
ADL after rehabilitation in participants without sarcopenia. 
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Table 5. Recent studies on sarcopenia in patients with hip fracture. 




Di Monaco (176)  Italy  138  1  58%  Discharge 
Flodin (177)  Sweden  79  4  21%  1 year 
Gonzalez-Montalvo 
(148) 
 Spain  479  1  17%  Discharge 
Ho (175)  China  239  1  W: 68% 
M: 74%  
 Discharge 
Landi (200)  Italy  127  1  34%  3 months 
Malafarina (178)  Spain  107  2  72%  Discharge 
Steihaug (224)  Norway  282  3  37%  1 year 
 
Table 5. N: number of participants in the study. M: men. W: women. 
In summary, our results for the prevalence and associations of sarcopenia are within 
the broad range of results from other studies, but the studies are not directly 
comparable due to the inclusion of different groups of patients and different methods 
for determining sarcopenia status. It is challenging to generalize results from these 
studies. The field of sarcopenia research needs larger studies, consensus on how to 
diagnose sarcopenia and harmonization of the reporting of results. 
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Abstract 
Introduction: Bioelectrical impedance analysis (BIA) is in wide-
spread use, but there is uncertainty about its validity in patients 
with metal implants or after acute hip fracture and surgery. We 
aimed to investigate the use of single frequency tetrapolar BIA in 
patients with hip fracture by answering the following questions: 1) 
Are BIA measurements affected by recent hip fracture and surgical 
repair? 2) Are BIA measurements affected by the presence of metal 
implants used in hip fracture surgery?  
Setting: Two hospitals in Bergen, Norway. 
Participants: A convenience sample of 203 acute hip fracture 
patients. 
Methods: Participants had their body composition measured by 
single frequency, tetrapolar BIA on the fractured and unfractured 
side of the body in the immediate postoperative period and at 
follow-up three months after hip fracture.  Measurements from 
fractured and unfractured side and measurements in hospital and 
at follow-up were compared. BIA readings for hips treated with 
cannulated screws, compression hip screw and hip arthroplasty 
were compared. 
Results: Resistance was lower on the side of the fractured hip 
compared to the unfractured side postoperatively, but not at 
follow-up. BIA readings did not differ by type of surgical implant.  
Conclusion: Recent fracture and surgery influences single frequency 
tetrapolar BIA resistance. The presence of surgical implants in the 
hip do not affect BIA measurements. If BIA is used in acute hip 
fracture patients, the contralateral side to the fracture should be 
measured. 
Keywords: Hip fracture, surgical implants, bioelectrical impedance 
analysis 
Introduction 
Bioelectrical impedance analysis (BIA) is a popular tool for 
determining body composition (1). BIA is painless, requires 
minimal mobility by the person being measured, is portable 
and does not expose users to radiation. It is found in a range 
of inexpensive consumer-targeted devices such as bathroom 
scales, it is used by healthcare workers to determine the 
health and nutritional status of persons (2) and it is in use in 
large population based studies of body composition (3). BIA 
has been validated in comparison with other methods of 
determining body composition such as Dual Energy x-ray 
absorptiometry (DXA), underwater weighing and Magnetic 
Resonance Imaging (4, 5). BIA has been validated 
prospectively as a method to determine elevated risk 
associated with adverse body composition profiles (6). We 
have previously used data from this study to validate BIA for 
determining muscle mass in hip fracture patients (7). 
Patients with acute hip fracture often have difficulty in 
walking and getting on to the examination table of a DXA, CT 
or MRI machine. BIA could be a valuable tool to investigate 
body composition in acute hip fracture patients. There are 
still concerns that BIA is not sufficiently validated since BIA is 
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influenced by health status and should be validated 
separately in each population (8-11). 
Many older persons live with surgical implants. It has 
been estimated that in the population aged 50+ in the UK 
there is a lifetime risk of 7-12% for receiving a total hip 
arthroplasty and 8-11% for total knee replacement (12). The 
validity of BIA to determine body composition in individuals 
with surgical implants is not determined, but is widely 
considered to be problematical (13, 14).  
When the proximal femur is fractured, the tension of 
surrounding tendons and muscle will often lead to 
dislocation of the fracture ends, which prevents skeletal 
healing. Surgical treatment of hip fracture involves surgical 
implants to fix the ends of the femur in their anatomical 
correct position to enable healing. There is a multitude of 
different surgical implants used for hip fracture repair, but 
the implants most commonly used can be categorized in 
three broad categories: hemiarthroplasty and total hip 
arthroplasty, cannulated screws and hip compression screws 
(Fig. 1 and 2). 
Fracture and surgery are associated with discontinuities 
of the tissue spaces and edema. The surgical implants are 
mainly made of metals such as steel, titanium, cobalt and 
chromium with use of other materials such as ceramics, 
hydroxyapatites and polyethylenes. These changes can 
potentially increase or decrease the electrical conductance, 
and it is difficult to predict how they will affect BIA 
measurements. If BIA is to be useful in the large group of 
acute hip fracture patients, or other patient groups 
undergoing surgery, it is important to determine the 
influence of fracture, surgery and surgical implants on BIA 
readings. The aim of this study is to answer the following 
research questions: 1) Are BIA measurements affected by 
recent fracture and surgical repair? 2) Are BIA 
measurements affected by the presence of metal implants 




Photo: Ole Martin Steihaug. 
 
Figure 1: Surgical implants used for hip fracture repair. From left: 
hemiarthroplasty of the hip, two cannulated screws and a 
compression hip screw. 
 
 
Fig. 2:  Plain film X-rays of hip fractures treated with different 
surgical implants. From Gjertsen (15). Reproduced with permission. 
 
Methods 
Patients admitted to hospital with suspected hip fracture 
were screened for inclusion in the study when the research 
staff was present on the hospital wards. Participants had to 
undergo surgical repair of acute hip fracture and be aged 
≥65 years, be ambulatory before the fracture, give informed 
consent, have an estimated remaining life expectancy of >3 
months and not have any disease of bone apart from 
osteoporosis or osteomalacia. Participants could not suffer 
from delirium, severe pain, have acute respiratory failure or 
be in shock at inclusion, but could develop these after 
inclusion. Participants were excluded if they had pacemakers 
or implanted defibrillators since these could be affected by 
BIA measurements. Patients could have preexisting surgical 
implants. Patients who were permanent residents of skilled 
nursing homes were not eligible for inclusion.  
  
Anthropometry 
Patients were weighed with indoor clothing. Height was 
primarily determined by wall mounted stadiometer. Some of 
the patients measured in hospital were not able to have 
their standing height measured. In these cases, self-reported 
height or length in bed was measured. Length in bed was 
measured while supine in a hospital bed, measured from 
heel to crown. Weight was determined by the available 
scale, often a chair-weight while in hospital. 
 
Bioelectrical impedance analysis 
BIA measurements in hospital were performed after hip 
fracture surgery when the patients had returned to the 
orthopedic ward from the recovery ward. The BIA resistance 
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and reactance (ohms) was obtained using single frequency 
tetrapolar BIA (RJL quantum systems III, RJL systems, USA) 
with an operating frequency of 50 kHz at 425 μA, and at 400 
μA and 50 kHz (Body impedance analyzer BIA 101 ASE, Akern 
Srl, Italy). Electrodes (RJL systems, USA) were placed on the 
skin at the wrist and ankle with participant supine in a 
hospital bed. The Quantum systems III was calibrated before 
measurements. Arms and legs were slightly spread so that 
they were not in contact with other parts of the body. The 
skin was not cleaned before applying the electrodes unless it 
was visibly or palpably dirty. Rings, bracelets and 
wristwatches were removed, if possible. Patients were not 
fasting and there was no systematic bladder voiding. 
Patients were measured first on one half of the body, then 
immediately afterwards on the other half using a new set of 
electrodes and by the same operator and using the same BIA 
device. All BIA measurements were performed by research 
nurses or the study physicians (MHK, OMS). We limited the 
sample to participants who had BIA readings from both 
fractured and unfractured side and did not have surgical 
implants in the opposite hip. All measurements were 
performed indoors with stable humidity and temperature 
between readings. The decision to measure both sides of the 




Participants were invited for a follow-up examination three 
months after admission to hospital. On the same day 
patients were measured by whole body DXA, BIA and 
anthropometry. Scheduling of the follow-up appointment 
was flexible to increase attendance and minimize the 
inconvenience for participants. 
 
Statistics 
The resistance of the fractured and unfractured hip was 
analyzed by mean difference with limits of agreement 
according to the method of Bland and Altman (16). The 
Bland-Altman methods was chosen because we considered 
the measurements of the fractured and the unfractured side 
of the body two alternative methods for determining whole-
body muscle mass. We assumed that BIA measurements on 
the side of the unfractured hip were not affected by the 
surgery or surgical implants of the fractured hip. We also 
assumed that any effect of fracture or surgery would be 
reduced at follow-up compared to while in hospital. 
Participants with pre-existing surgical implants in the 
unfractured hip were excluded from analysis. Resistance and 
reactance of the fractured side was compared with the 
unfractured side using paired T-test, in hospital and at 
follow-up, for a total of four comparisons. For determining 
the influence of surgical implants on resistance and 
reactance, the difference between the resistance and 
reactance of the fractured and unfractured hip was analyzed 
by analysis of variance using category of surgical implant. 
The categories were hip screws, compression hip screw and 
hip arthroplasty. The arthroplasty category constituted both 
hip hemiarthroplasty and total hip arthroplasty. P ≤0.05 was 
considered statistically significant. Analysis was by Stata 
Statistical Software: Release 14. StataCorp LP, USA. 
 
Ethics 
The research was conducted according to the declaration of 
Helsinki. Participants were given written and verbal 
information about the study on the first day and were asked 
to sign the consent form on a subsequent day. This enabled 
time for deliberation and to consult their next of kin. 
Participants were included when they had been mobilized to 
sitting upright and with adequate pain relief. In situations 
where the capacity for consent was in doubt, experienced 
medical doctors and the rest of the team treating the 




Table 1: Characteristics of the participants. 
Age, years (SD) 80 (8) 
Female, n (%) 151 (76) 
Right sided fracture, n (%) 109 (54) 
Type of surgical implant, n (%) 
  
Cannulated screws 44 (22) 
Hemiarthroplasty 62 (31) 
Hip compression screw 83 (41) 
Total hip arthroplasty 8 (4) 
Femoral nail 6 (3) 
 
 In hospital At follow-up 
Height (SD), cm 166 (10) n=136 164 (9) n=162 
Weight (SD), kg 66 (16) n=136 64 (14) n=162 
 
Fractured hip 
Resistance (SD), Ohm 491 (95) n=134 555 (95) n=157 
Reactance (SD), Ohm 46 (31) n=134 49 (13) n=157 
 
Unfractured hip 
Resistance (SD), Ohm 527 (99) n =131 552 (89) n =158 
Reactance (SD), Ohm 53 (51) n =131 53 (23) n =158 
 
 
Table 2: Pairwise comparisons of BIA readings on fractured and unfractured hips. 
 Fractured Unfractured P-value N 
Resistance 
Hospital 496 (98) 527 (101) 0.0007 81 
Follow-up 553 (98) 550 (92) 0.4 134 
Reactance 
Hospital 45 (20) 56 (64) 0.068 81 
Follow-up 49 (14) 52 (23) 0.061 134 
 
During the period of inclusion 843 patients were 
operated on for hip fracture, 203 were included and 163 
returned for follow-up. All participants were Caucasian. BIA 
was performed at a median of 5 (IQR 4-7) days after hip 
fracture, which was a median 4 (IQR 2-5) days after surgery. 
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The number of days from admission to follow-up was a 
median 112 days (IQR 98-133). 
 
 
Fig. 3: Bland-Altman plot of difference in resistance between 
fractured and unfractured hip postoperatively after hip fracture. 
Red lines are the mean, upper and lower limits of agreement 
(mean bias ±1.96 standard deviations). 
 
 
Fig. 4: Bland-Altman plot of difference in resistance between 
fractured and unfractured hip 3 months after hip fracture. Red 
lines are the mean, upper and lower limits of agreement (mean 
bias ± 1.96 standard deviations). 
 
 
Fig. 5: Change in difference between fractured and unfractured hip 
from hospital to follow-up. Symbols indicates type of surgical 
implant and difference between fractured and unfractured hip in 
hospital. The vertical line indicates the magnitude of the change in 
difference between fractured and unfractured hip from hospital to 
follow-up. 
In hospital, resistance on the side of the body with the 
fractured hip was lower than the side with the unfractured 
hip, 496 (SD 98) ohm vs 527 (SD 101) ohm, P=0.0007. Table 
2. The limit of agreement was wider in hospital compared to 
at follow-up, indicating that fracture and surgery affected 
BIA measurements. Figure 3 and 4. The difference in 
resistance or reactance between fractured and non-
fractured hip did not vary by type of surgical implant, either 
during hospital stay or at follow-up. 
 
Discussion 
Our results show that BIA is not affected by the type of 
surgical implants of the hip. There is a statistically and 
clinically relevant effect of fracture and/or surgery on 
resistance in the fractured hip, including important outliers. 
The clinical relevance is illustrated by the mean difference 
and limit of agreement of appendicular lean mass 
determined by BIA on the fractured and the unfractured 
side, using the equation of Sergi et al (17). In hospital the 
mean difference is 0.2 kg (n=57), with a large limit of 
agreement of -5.7 to 6.0 kg. At follow-up the limit of 
agreement is narrower, -3.0 to 2.6 kg, with a mean bias of  
-0.2 kg. A clinically relevant change in appendicular lean 
mass is of a magnitude of 1kg  (7). A practical solution to this 
problem is to measure the unfractured side.  
We performed the BIA measurements in a correct and 
competent manner, but we did not adhere to all 
recommendations for increasing precision of the BIA 
measurements. Some of these recommendations are 
controversial and the strict adherence to all such 
recommendations is impractical (18).  
We found that resistance is affected by recent fracture or 
surgery. Our results do not inform us if it is the fracture, the 
surgery or a combination that influences BIA readings. A 
future study which examined BIA readings after fracture, but 
before surgery could possibly answer that question. We are 
not aware of previous studies on the effect of fracture and 
surgery on BIA measurements. A study by Villani et al used 
BIA in patients with acute hip fracture (19), but they 
performed all measurements on the right side, irrespective 
of the side of fracture. A study by Gonzalez-Montalvo et al 
used BIA after hip fracture and before surgery, but they only 
measured BIA on the contralateral side to the fracture (20). 
Our results indicate that BIA is not affected by type of 
surgical implant of the three categories we examined. Hip 
arthroplasty, cannulated screws and compression hip screws 
have different masses and placement in the hip region. We 
believe that if the shape and the approximate shape of the 
different tissues of bone, fat and skeletal muscle mass are 
unchanged the type of surgical implant does not matter. It 
seems likely that more severe traumatic injuries where the 
shape of the hip is fundamentally changed or a tissue 
compartment is removed can result in larger changes in 
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It is possible that other acute changes could influence 
BIA readings in hospital. Patients could suffer from fluid and 
electrolyte disturbances due to illness, dehydration or fluid 
retention due to heart failure. We do not have information 
about these factors.  
Even if the included population is not generalizable to all 
hip fracture patients, we believe the edema and tissue 
destruction associated with fracture and surgery is 
representative of all hip fracture patients. The surgical 
implants used in this study, predominantly compression hip 
screws, hip arthroplasty and cannulated screws, are the 
same as most patients with hip fracture are surgically 
treated. 
This is the first time BIA is critically examined in a setting 
of acute tissue destruction and our findings indicate that 
care must be taken if BIA is to be used in similar settings, 
such as in other forms of surgery or trauma. 
We note that the wide dispersion of results with outliers 
continue to be a problem for precise BIA measurements at 
an individual level. 
Conclusion 
Tetrapolar single frequency BIA is affected by recent surgery 
and fracture, but not by type of surgical implant. BIA can be 
used to determine body composition in patients who have 
suffered hip fracture. We recommend measuring the 
contralateral side to the hip fracture in the immediate 
postoperative period. This supports using BIA to determine 
body composition in patients with surgical implants. 
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Sarcopenia is prevalent in older persons and is a risk factor for falls, fractures, and mortality.
The aim of this study was to determine a) the feasibility of determining sarcopenia in patients
with acute hip fracture, b) the prevalence of sarcopenia and c) associations of sarcopenia
with nutritional status and comorbidities.
Methods
A multicenter cross-sectional study on sarcopenia in male and female patients with acute
hip fracture. Participants were previously ambulatory and living in the community. Sarcope-
nia was assessed postoperatively with muscle mass estimated by anthropometry using tri-
ceps skinfold, arm circumference, height, weight and sex. Grip strength was measured by
Jamar dynamometer and pre-fracture mobility was by self-report using the New Mobility
Score.
Results
Out of 282 patients, 202 were assessed for sarcopenia of whom 74 (37%) were diagnosed
as sarcopenic. Sarcopenia was associated with age, odds ratio (OR) 1.4 per 5 years, 95%
confidence interval (CI) [1.1, 1.8], ASA Physical Status Classification System score, OR 2.3
per point, 95% CI [1.3, 4.3] and number of medications at discharge, OR 1.2 per medication,
95% CI [1.0, 1.3] and inversely associated with BMI, OR 0.8, 95% CI [0.7, 0.9] and serum
albumin, OR 0.9, 95% CI [0.8,1.0].
Conclusions
Thirty-seven percent of assessed subjects were diagnosed with sarcopenia. Our data dem-
onstrates that the prevalence of sarcopenia is associated with older age, malnutrition and
comorbidities. Determining sarcopenia at the bedside was feasible in postoperative hip
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fracture patients by using grip strength, estimation of muscle mass by anthropometry and
self-reported mobility.
Introduction
Sarcopenia is a syndrome characterized by reduced muscle mass and reduced muscle function
and an increased risk of disability and death [1]. Sarcopenia has recently been recognized as an
independent condition with an International Classification of Disease Code [2]. Sarcopenia is
a well-known risk factor for both falls and fractures: Reduced muscle strength makes it more
difficult to regain lost balance and decreases the mechanical loading of the skeleton leading to
reduced adaptive bone remodeling [3, 4]. Half of all hip fracture survivors will develop perma-
nent impairments in mobility and 10–20% will become institutionalized [5]. The prevalence of
sarcopenia in hip fracture patients is 17–74%, depending on population and definition of sar-
copenia [6–8]. Norway has one of the highest rates of hip fracture in the world [9] and it is esti-
mated that 4–5% of all deaths in the Norwegian population aged 50+ are attributable to hip
fractures [10]. The reasons for this are unknown and sarcopenia is a candidate for explaining
some of this excess risk. There has been only moderate improvement in the outcomes of
patients with hip fracture since the 1960s [11]. Studies indicate that better outcomes are possi-
ble by involving geriatricians and increasing the intensity of rehabilitation efforts [12, 13].
Exercise and nutritional interventions are important interventions for sarcopenia [14] and in
rehabilitation after hip fracture [15]. Smoking cessation and reduction of harmful alcohol
intake can possibly reduce sarcopenia [16–18] and the risk of hip fracture [19–22]. There is no
consensus on how sarcopenia should be operationalized. The three main methods are: low
muscle mass as recommended by Janssen et al [23], low muscle mass with one of reduced
physical performance or muscle strength, as recommended by the European Working Group
on Sarcopenia in Older People (EWGSOP) [1] and low muscle mass and low grip strength, as
recommended by the Foundation for the National Institutes of Health Biomarkers Consor-
tium Sarcopenia Project [24]. These recommendations are based on studies on older people
living in the community. Investigating the feasibility of determining sarcopenia in acute hip
fracture patients is necessary before assessment of sarcopenia can be introduced in clinical
practice. The aims of this study are to:
1. assess the feasibility of determining sarcopenia in acute hip fracture patients.
2. determine the prevalence of sarcopenia and investigate how sarcopenia is associated with
risk factors for adverse clinical outcomes: older age and male sex [10], nutritional risk and
low albumin, low vitamin D, low body mass index (BMI) [25], comorbidities and polyphar-
macy, and impairments in activities of daily living [26].
3. Investigate the separate associations of muscle mass, grip strength and mobility with the
same risk factors.
Materials and methods
This is a cross-sectional study on sarcopenia in patients with hip fracture. Patients were
included in the immediate postoperative period at three hospitals in Norway, 2011–2013.
Patients eligible for participation were 65 years or older, ambulatory before the hip fracture
and willing to provide written informed consent. Permanent residents of nursing homes,
patients who were medically unstable or had a life expectancy of less than 3 months, were
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excluded. Collection of data was by the authors or research personnel, with different teams at
the different hospitals. All personnel received training and guidance from the first author
(OMS). Research staff were not present on the wards at all times, such as during weekends or
holidays. Pre-fracture independence in activities of daily living (meals, bathing, grooming,
dressing, continence, toileting, transferring and ambulation) was determined by the modified
Barthel index (B-ADL), a summary score with a range 0–20 [27]. Nutritional risk was assessed
using the Nutritional Risk Screening Score 2002 (NRS 2002) [28]. The NRS 2002 is a screening
tool for identifying hospitalized patients likely to benefit from nutritional interventions. It is
scored 0–3 points for nutritional state, 0–3 points for illness severity and an additional point if
aged>70 years, for a total of score 0–7. Patients with hip fracture will typically be given one
point for illness severity. Serum albumin and 25-OH vitamin D was measured in the fasting
state, preoperatively at one hospital and postoperatively at two hospitals. Participants use of
supplemental vitamin D (as tablets or cod liver oil) was determined by food frequency ques-
tionnaire and chart review. Comorbidities were assessed by chart review for determining the
Charlson index [29]. The Charlson index is a list of chronic diseases, weighted by severity,
that has been found to predict mortality. The American Society of Anesthesiologists Physical
Status Classification System (ASA) score is a grading system of the preoperative health of sur-
gical patients, range 1–5 [30]. The number of medications used regularly and as needed was
assessed at discharge.
Determining sarcopenia
Participants were identified as being “not sarcopenic” or “sarcopenic” using the criteria recom-
mended by the EWGSOP [1]. To be categorized as sarcopenic participants had to have low
muscle mass and one of either low grip strength or low mobility. Total body muscle mass was
estimated by anthropometry by the method of Heymsfield et al. [31] using gender, height, arm
circumference and triceps skinfold. Arm circumference was measured on the right arm at the
mid-point between the acromion and olecranon process with the arm hanging down. Triceps
skinfold was measured on the posterior aspect of the same arm at the same level using a skin-
fold caliper (Harpenden, Baty International, Great Britain). Measurements were repeated until
two readings were within 1mm. The values for total body muscle mass were converted to ap-
pendicular lean mass (ALM) using model 1 of Kim et al [32]. It has previously been reported,
using data from this study, that anthropometry by the Heymsfield method was able to identify
patients with low muscle mass, compared to Dual Energy X-ray absorptiometry (DXA) [33].
Patients were weighed in light clothing using the scales available on the hospital wards. Height
was measured by wall-mounted stadiometer, except for a few cases where the patient was
unable to stand. In those cases, height measured at other time-points, self-reported height or
the distance from heel to crown while lying in bed was used. Cut-points for low muscle mass
were chosen based on the recommendations of the EWGSOP [1], ALM divided by height
squared,7.25 kg.m-2 for men and5.67 kg.m-2 for women.
Grip strength was measured three consecutive times in one hand and immediately after-
ward on the other hand with a Jamar Hydraulic Dynamometer (Sammons Preston, USA)
while the patient was sitting in bed or on a chair, with the elbow flexed, the wrist in the neutral
position, and with verbal encouragement. There was a brief interval between attempts while
the dynamometer was repositioned. The single best value of all six measurements was used.
Low grip strength was defined as 30kg for men and 20kg for women, as recommended by
the EWGSOP[1]. Grip strength and muscle mass was determined at daytime in the mainly
bed-bound participants without consideration of meals, recent physical activity, bladder void-
ing or hydration.
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Mobility was determined by the New Mobility Score (NMS). The NMS assesses mobility in
the two weeks prior to the fracture by interview. It ranges 0–9; a score of zero indicates that the
person is not ambulatory and nine indicates an ability to walk without assistance while shop-
ping. The NMS predicts physical performance and mortality after hip fracture [34–36]. Low
mobility was defined as NMS <5, based on the cut-point recommended for predicting mortal-
ity after hip fracture [34]. Anthropometry for determining muscle mass was chosen because it
is an established technique for determining body composition [37], is in common use [38],
inexpensive and more easily performed on patients with pain on mobilization compared to
DXA. Estimating muscle mass by anthropometry in patients with acute hip fracture requires
some effort, mainly in determining height and weight. Grip strength is quickly measured, but
requires an alert patient able to take instruction and with reasonable hand function. The NMS
was chosen because it was assumed that some participants would be unable to perform tests of
physical performance and because self-reported mobility has been found to have similar psy-
chometric and predictive properties to objective tests [39]. Mobility by the NMS can be deter-
mined in a minute in a bed-bound patient, as long as the patient or proxy is able to answer
questions about pre-fracture mobility.
Ethics
All participation was by written, informed consent. Patients were included in the postoperative
phase as pain and anxiety is less after surgery. Participating hospitals, Haraldsplass Deaconess
Hospital, Haukeland University Hospital and Diakonhjemmet Hospital, and the Regional
Committee on Medical and Health Research Ethics approved the study (2011/1322/REK sør-
øst B). The study was conducted according to the principles of the Declaration of Helsinki
[40].
Statistical analysis
Participants were described according to sarcopenia status with median and interquartile
range (IQR) or mean and standard deviation (SD) and the differences between groups were
analyzed with the Mann–Whitney–Wilcoxon test. The association between sarcopenia as
dependent variable and the different risk factors as independent variables was analyzed in sep-
arate logistic regression analyses with odds ratios (OR) and 95% confidence intervals (95%
CI). Separate analysis was also performed with low muscle mass, low grip strength and low
mobility as dependent variables. Regression analyses were adjusted for age, sex and BMI and
analysis of vitamin D was additionally adjusted for using supplemental vitamin D. Age, sex
and BMI were included in the models because they are established associations of grip strength
and muscle mass [41]. P0.05 was considered significant. Analysis was by Stata 14.0 (Stata
Corp., USA)
Results
Of the included 282 patients with acute hip fracture, low muscle mass was found in 61% (118/
194), low grip strength in 52% (116/222), and low mobility in 8% (20/244). Sarcopenia preva-
lence was 37% (74/202). Fig 1 illustrates which participants were assessed for mobility, grip
strength and muscle mass. Participants with sarcopenia were older, had evidence of nutritional
risk as indicated by lower BMI, lower albumin and higher scores on the NRS 2002. Participants
with sarcopenia were also characterized by longer hospital stay, higher ASA score at operation,
used a greater number of medications at discharge and had more impairments in activities of
daily living before the hip fracture (Table 1). Participants with missing values for sarcopenia
status had lower B-ADL scores compared to those who did not have missing values, and
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women with missing values had lower grip strength and mobility. Reasons for missing values
included patients being too ill for or refusing specific examinations, or that they were dis-
charged before the data collection was completed. Intracapsular fractures constituted 59% of
the fractures. For 8% of patients this was their second hip fracture. Grip strength and ALM
were determined at a median of 4 days after surgery, the interquartile range was 3 to 6 days,
and the total range was from the day before surgery to 24 and 34 days after surgery, respec-
tively. Supplemental vitamin D was used by 50% and was associated with a significantly higher
serum vitamin D, 63 (SD 26) versus 47 (SD 23) 10−6 mol.m-3 (nmol/L). During the period of
inclusion, 1592 patients were admitted for hip fracture surgery at the three hospitals.
The results of regression analysis for sarcopenia are presented in Fig 2 and Table 2. In
adjusted analysis, sarcopenia was positively associated with age, OR 1.4 for each 5-year
increase, 95% CI [1.1, 1.8], ASA score, OR 2.4, 95% CI [1.3, 4.3], and number of medications
at discharge, OR 1.2, 95% CI [1.0, 1.3]. BMI, OR 0.8, 95% CI [0.7, 0.9] and serum albumin, OR
0.9 95% CI [0.8, 1.0], were associated with not having sarcopenia.
Results for the adjusted regression analyses for low muscle mass, low grip strength and low
mobility are presented in Table 3. Low muscle mass, using sex-specific cut-points, was associ-
ated with male gender, OR 5.4, 95% CI [1.8, 15.8]. BMI and albumin were negatively associated
with low muscle mass. Low grip strength was associated with increasing age and ASA score
and associated with lower BMI and albumin. Low mobility was associated with age and num-
ber of medications at discharge and negatively associated with impairments in activities of
daily living.
Discussion
The aims of this study were to determine the feasibility of identifying sarcopenia in acute hip
fracture patients, estimate the prevalence of sarcopenia and the associations between sarcope-
nia and risk factors for adverse clinical outcomes after hip fracture. Two hundred and eighty-
two participants were included and sarcopenia status was determined in 202. Determining sar-
copenia status using the bedside methods of anthropometry, grip strength and the NMS was
feasible, is relevant to clinicians as a bedside tool, and is possible to implement on busy hospital
wards. The rate of 28% of unsuccessful assessments for sarcopenia indicates that further
improvement is warranted. Feasibility would be improved if muscle mass could be estimated
without determining height or weight. Malmstrom and Morley have recommended the simple
screening tool SARC-F as method to diagnose sarcopenia [42]. The SARC-F is a questionnaire
containing 4 questions about physical performance and one question about falls in the last
Fig 1. Participants assessed for mobility, grip strength and muscle mass.
https://doi.org/10.1371/journal.pone.0184780.g001
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year. Future research should investigate the role of the SARC-F in patients with hip fracture.
In the present study, sarcopenia was determined by anthropometry, which is considered a less
precise method compared to DXA or bioelectrical impedance analysis. Anthropometry is ade-
quate at identifying low muscle mass [43] and is able to identify increased mortality risk in
males [44, 45]. Because of pain and severe mobility impairment, it is difficult to measure mus-
cle mass by DXA in patients with hip fracture. Compared to anthropometry, DXA is more
expensive, requires bulky equipment, takes longer time to do, and requires more trained per-
sonnel. DXA estimates of muscle mass are sensitive to acute changes in muscle water content,
such as seen with changes in muscle glycogen or creatinine due to feeding or dehydration [46].
A strength of the present study is that participants were recruited at three separate hospitals.
This reduced the influence of investigator specific factors such as confirmation bias and
reduced the influence of hospital related factors such as differences in quality of care, differ-
ences in catchment populations, or selective recruitment processes. A multi-center study is
leads to greater generalizability of results. A weakness of the multi-center design was less con-
trol of the conduct of the study, leading to loss of information on participants who were
screened but not included and missing values.
Three recent cross-sectional studies have investigated sarcopenia in acute hip fracture
patients using the EWGSOP framework. There was great variation in the prevalence of
Table 1. Characteristics of participants by sarcopenia status.
Not sarcopenic, n = 128 Sarcopenic, n = 74
Age, years [IQR] 77.5 [70,5–85] n = 128 82 [76–86] n = 74**
Female, N (%) 99 (77) n = 128 53 (72) n = 74
Length of hospital stay, days [IQR] 6 [5–8] n = 128 7.5 [6–11] n = 74**
BMI, kg.m-2 [IQR] 25.3 [22.7–28.0] n = 110 22.0 [19.5–24.2] n = 67**
NRS 2002 [IQR] 2 [2–2] n = 117 2 [2–3] n = 70**
Albumin, kg.m3 (SD) 35.9 (5.2) n = 113 32.6 (6.3) n = 59**
User of vitamin D supplement, N (%) 60 (50) n = 119 31 (46) n = 56
Vitamin D, 10−6 mol.m-3 [IQR] 53 [34–75] n = 111 48 [31–66] n = 64
Charlson index [IQR] 0.5 [0–1] n = 128 1 [0–2] n = 74
ASA score [IQR] 2 [2–3] n = 128 3 [2–3] n = 74**
Medications, number [IQR] 7 [5–10] n = 128 8 [7–11] n = 73**
B-ADL [IQR] 20 [19–20] n = 88 20 [18–20] n = 57*
ALM.height2, kg-.m-2 [IQR] 6.4 [5.6–7.4] n = 115 4.7 [4.0–5.2] n = 74**
ALM.height2 ─ Women, kg-.m-2 [IQR] 6.3 [5.6–7.1] n = 90 4.4 [4.0–5.1] n = 53**
ALM.height2 ─ Men, kg-.m-2 [IQR] 7.1 [6.1–7.8] n = 25 5.1 [4.5–5.8] n = 21**
Grip strength, kg [IQR] 25 [21–32] n = 126 17 [12–20] n = 74**
Grip strength ─ Women, kg [IQR] 22 [20–26] n = 96 14 [12–18] n = 53**
Grip strength ─ Men, kg [IQR] 40 [34–43] n = 29 24 [20–27] n = 22**
New Mobility Score [IQR] 9 [7–9] n = 127 7 [5–9] n = 71**
New mobility score–Women [IQR] 9 [7–9] n = 98 7.5 [5–9] n = 52**
New mobility score–Men [IQR] 9 [7–9] n = 29 7 [5–9] n = 19*
IQR: Values are medians and interquartile range. SD: Values are means and standard deviation.
* P0.05 or
**P0.01 is the probability for difference by Mann–Whitney–Wilcoxon test.
BMI: Body mass index. ASA score: The ASA Physical Status Classification System. Barthel ADL: Barthel activities of daily living. ALM: Appendicular lean
mass.
https://doi.org/10.1371/journal.pone.0184780.t001
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sarcopenia, 12–74% in men and 18–68% in women [6–8]. This variation in the prevalence of
sarcopenia is likely due to differences in patient groups, measurement techniques and the use
of different cut-points. The studies were from Hong Kong, Spain and Italy. Ho et al studied
Chinese patients with hip fracture and used lower cut-points for grip strength at<26kg for
men and<18kg for women. Muscle mass was determined by DXA a mean 14 days after the
fracture. In the study by Gonzalez-Montalvo et al sarcopenia was determined before surgery.
Muscle mass was determined by bioelectrical impedance and the cut-point for low muscle
mass was higher than in the present study, at<6.68 kgm-2 in women and<8.31 kgm-2 in
Fig 2. Sarcopenia and risk factors. Adjusted regression analysis using age, sex and BMI as covariates and
the analysis of vitamin D additionally adjusted for being a user of supplemental vitamin D. Estimate for age is
for 5-year increase and estimate for vitamin D is for increase of 10−5 mol.m-3 (10 nanomol/L).
https://doi.org/10.1371/journal.pone.0184780.g002
Table 2. Predictors of sarcopenia.
Univariable analysis Adjusted analysis
OR [95% CI] P-value R2 n OR [95% CI] P-value R2 n
Age, 5 years 1.4 [1.2,1.7] <0.001 0.05 202 1.4 [1.1, 1.8] 0.003 0.18 177
Female 0.7 [0.4, 1.4] 0.4 <0.01 202 0.6 [0.3, 1.4] 0.3 0.18 177
Male 1.4 [0.7, 2.6] 0.3 <0.01 202 1.6 [0.7, 3.5] 0.3 0.18 177
BMI, kg.m-2 0.8 [0.7, 0.9] <0.001 0.13 177 0.8 [0.7, 0.9] <0.001 0.18 177
NRS 2002 2.2 [1.5, 3.2] <0.001 0.08 187 1.2 [0.8, 1.9] 0.4 0.19 168
Albumin, kg.m-3 0.9 [0.8, 1.0] <0.001 0.06 172 0.9 [0.8, 1.0] 0.001 0.19 147
Vitamin D, 10−5 mol.m-3 0.9 [0.8, 1.1] 0.3 <0.01 175 1.0 [0.8, 1.1] 0.6 0.17 141
Charlson index 1.1 [0.9, 1.4] 0.3 <0.01 202 1.2 [0.9, 1.5] 0.1 0.18 177
ASA score 2.8 [1.7, 4.7] <0.001 0.06 202 2.4 [1.3, 4.3] 0.004 0.21 177
Medications 1.1 [1.0, 1.2] 0.005 0.03 201 1.2 [1.0, 1.3] 0.004 0.22 176
B-ADL 0.8 [0.6, 1.0] 0.020 0.03 145 0.8 [0.6, 1.0] 0.066 0.25 139
Sarcopenia as dependent variable in separate logistic regression analyses. Adjusted analyses are with age, gender and BMI as covariates and for vitamin D
as a predictor is additionally adjusted for being a user of supplemental vitamin D. OR: Odds ratio. CI: Confidence interval. R2: Adjusted R2. BMI: Body mass
index. ASA score: the ASA Physical Status Classification System, points. B-ADL: Barthel activities of daily living. Vitamin D 10−5 mol.m-3 (10 nmol/L).
https://doi.org/10.1371/journal.pone.0184780.t002
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men. The study by Di Monaco et al was on Italian women selected to undergo intensive reha-
bilitation after hip fracture. Di Monaco et al found that the Barthel index at the start of rehabil-
itation was lower in the group with sarcopenia, while both the study by Gonzalez-Montalvo
et al. and Di Monaco et al. reported an association between low BMI and sarcopenia [6, 8].
Compared to the patients in the Norwegian Hip Fracture Register, which covers 86–94% of
all hip fractures in Norway, the patients in our study had a mean age of 79.4 years and a mean
ASA score of 2.5, compared to 80.0 years, and an ASA score of 2.7 in the register [47]. Our
results are not generalizable for hip fracture patients from nursing homes, or patients with
severe physical or cognitive impairment. However, the relatively robust participants in our
study are more likely to benefit from intensive rehabilitation compared to frailer patients, as
found by a study by Prestmo et al on the benefit of orthogeriatric care in frail versus fit hip
fracture patients [48].
Increasing age was associated with sarcopenia and low grip strength, but not with low mus-
cle mass, which is in agreement with previous research on healthy older people [49]. There is a
significant association between low BMI and sarcopenia in other studies on sarcopenia in hip
fracture patients [6, 8], which is consistent with the finding that BMI is negatively associated
with sarcopenia, muscle mass and grip strength. Nutritional risk by NRS 2002 was associated
with sarcopenia in unadjusted analysis, but not in adjusted analysis. This is explained by how
NRS 2002 is scored, with higher scores for low BMI and age greater than 70 years. The NRS
2002 was developed as screening tool for identifying hospitalized patients likely to benefit
from nutritional interventions, and is not primarily a tool to diagnose undernutrition. Albu-
min is a biomarker of undernutrition and is a risk factor for mortality in hip fracture patients
[50]. In the present study, low albumin was associated with sarcopenia, low muscle mass and
low grip strength. Serum albumin and vitamin D are reduced in inflammatory states [51] such
as in hip fracture or surgery, and thus caution is warranted when interpreting this association.
There are numerous studies describing important associations between serum albumin and
Table 3. Muscle mass, grip strength, mobility and risk factors.
Low muscle mass Low grip strength Low mobility
OR [95% CI] n P R2 OR [95% CI] n P R2 OR [95% CI] n P R2
Age, 5 years 1.0 [0.8, 1.3] 170 0.97 0.27 1.6 [1.3, 2.0] 186 <0.001 0.15 1.5 [1.0, 2.2] 194 0.038 0.07
Female 0.2 [0.1, 0.6] 170 0.002 0.27 1.2 [0.6, 2.6] 186 0.6 0.15 0.6 [0.2, 2.2] 194 0.5 0.07
Male 5.4 [1.8, 15.8] 170 0.002 0.27 0.8 [0.4,1.7] 186 0.6 0.15 1.6 [0.4, 5.5] 194 0.5 0.07
BMI, kg.m-2 0.7 [[0.6, 0.8] 170 <0.001 0.27 0.9 [0.8, 1.0] 186 0.003 0.15 0.9 [0.8, 1.0] 194 0.2 0.07
NRS 2002 1.6 [0.8, 3.3] 163 0.2 0.27 1.1 [0.8, 1.7] 175 0.6 0.17 1.5 [0.9, 2.6] 182 0.1 0.10
Albumin, kg.m-3 0.9 [0.8, 0.9] 141 0.001 0.31 0.9 [0.9, 1.0] 154 0.006 0.17 1.0 [0.9, 1.1] 163 0.9 0.03
Vitamin D, 10−5 mol.m-3 1.0 [0.8, 1.1] 138 0.6 0.31 0.9 [0.7, 1.0] 147 0.059 0.17 0.9 [0.6, 1.2] 154 0.4 0.10
Charlson index 1.1 [0.8, 1.4] 170 0.7 0.27 1.1 [0.9, 1.4] 186 0.4 0.15 1.3 [0.9, 1.8] 194 0.2 0.09
ASA score 1.9 [1.0, 3.6] 170 0.052 0.29 1.8 [1.0, 3.0] 186 0.038 0.16 2.3 [0.9, 6.2] 194 0.09 0.10
Medications 1.0 [0.9, 1.2] 169 0.5 0.28 1.1 [1.0, 1.2] 185 0.08 0.16 1.2 [1.0, 1.5] 193 0.015 0.13
B-ADL 0.9 [0.6, 1.3] 131 0.5 0.31 0.8 [0.6,1.0] 148 0.052 0.19 0.5 [0.3, 0.7] 149 <0.001 0.34
Low muscle mass, low grip strength and low mobility as dependent variables in separate logistic regression analyses. All analyses are adjusted for age,
gender and BMI and analyses for serum vitamin D are additionally adjusted for use of supplemental vitamin D. OR: Odds ratio. CI: Confidence interval. n:
number of participants without missing values and available for analysis. P: Probability of association being random. R2: Adjusted R2. BMI: Body mass
index. ASA score: the ASA Physical Status Classification System, points. B-ADL: Barthel activities of daily living. ALM: Appendicular lean mass. Low
muscle mass7.25 kg.m-2for men and5.67 kg.m-2 for women, defined as appendicular lean mass divided by height squared. Low grip strength is 30kg
for men and20kg for women. Low mobility is NMS <5. Vitamin D 10−5 mol.m-3 (10 nmol/L).
https://doi.org/10.1371/journal.pone.0184780.t003
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clinical outcomes in patients with hip fracture, where serum albumin has been measured both
before [52], and after surgery [53]. Visser et al [54] found an increased loss of muscle mass in
participants with low serum albumin in older persons living in the community, which indi-
cates a relevant association between sarcopenia and albumin in a setting without acute in-
flammation. The finding in this study that low BMI and serum albumin are associated with
sarcopenia supports the hypothesis that nutrition and sarcopenia are associated and that nutri-
tional interventions such as supplemental protein, specific amino acids or β-hydroxy-β-
methylbutyrate can improve muscle mass, strength and physical performance [55–58]. The
present study found no association between serum vitamin D and sarcopenia, which is in
agreement with the study by Gonzalez-Montalvo et al [6] on sarcopenia in hip fracture
patients. Participants in this study had higher levels of serum vitamin D compared to other
studies on patients with hip fracture [59, 60], likely explained by the fact that half the partici-
pants used supplemental vitamin D before the fracture. The ASA score and the number of
chronic diseases are predictors of mortality after hip fracture [26]. Polypharmacy or use of
potentially inappropriate medication has been found to increase the risk of hip fracture [61],
the risk of injurious falls after hip fracture [25], and reduced mobility and grip strength in hos-
pitalized elderly [62]. In the present study, there was an association between higher ASA score,
using more medications and sarcopenia, but no association between the Charlson index and
sarcopenia. There is probably a causal relationship between comorbidities, polypharmacy and
sarcopenia. Future studies should examine the effect on sarcopenia by reducing inappropriate
polypharmacy [63]. The participants in the present study had low values on the Charlson
index with a median score of one. Many common chronic conditions, such as hypertension,
angina or osteoporosis are not counted as part of the Charlson index and it is possible that the
index does not fully capture the burden of chronic diseases.
The associations found in the present study between sex and low muscle mass, low grip
strength and reduced mobility, had wide confidence intervals. This indicates that the methods
for determining muscle mass, grip strength and mobility and risk factors were insufficiently
precise or that there were too few male participants with data on sarcopenia status in the
study, only 50 out of 202. Men have a worse prognosis after hip fracture with a 4.6-fold
increased mortality after hip fracture compared to 2.8- fold increase in women [10]. The rea-
sons for this are unclear and at odds with other research that has found a greater prevalence of
physical frailty in women [64]. Di Monaco et al [65] found that male patients with hip fracture
were more likely to have low muscle mass using sex specific cut-points, and our results agree
with this. Future studies should examine if low muscle mass in men with hip fracture can
explain the excess mortality.
Conclusion
Among previously ambulatory, community-living hip fracture patients, the prevalence of sar-
copenia was 37%. Sarcopenia was positively associated with age, ASA score and polypharmacy,
and negatively associated with BMI and albumin. By using anthropometry, grip strength and
self-reported mobility it is feasible to determine sarcopenia at the bedside in postoperative hip
fracture patients.
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Abstract
Background: Patients with hip fracture frequently have sarcopenia and are at great risk of loss of mobility. We have
investigated if sarcopenia predicts change in mobility after hip fracture.
Methods: This is a prospective, multicenter observational study with one-year follow-up. Patients with hip fracture
who were community-living and capable of walking before the fracture were included at three hospitals in Norway
(2011–2013). The primary outcome of the study was change in mobility, measured by the New Mobility Score
(NMS). Sarcopenia was determined postoperatively by anthropometry, grip strength, and NMS.
Results: We included 282 participants and sarcopenia status was determined in 201, of whom 38% (77/201) had
sarcopenia, 66% (128/194) had low muscle mass, 52% (116/222) had low grip strength and 8% (20/244) had low
pre-fracture mobility (NMS < 5). Sarcopenia did not predict change in mobility (effect 0.2 points; 95% CI –0.5 to 0.9,
P = 0.6), but it was associated with having lower mobility at one-year (NMS 5.8 (SD 2.3) vs. 6.8 (SD 2.2), P = 0.003),
becoming a resident of a nursing home (odds ratio 3.2, 95% CI 0.9 to 12.4, P = 0.048), and the combined endpoint
of becoming a resident of a skilled nursing home or death (odds ratio 3.6, 95% CI 1.2 to 12.2, P = 0.02).
Conclusions: Sarcopenia did not predict change in mobility in the year after hip fracture.
Keywords: Activities of daily living, Hip fractures, Independent living, Mobility limitation, Skilled nursing facilities,
Sarcopenia
Background
A hip fracture is associated with severe and persisting mo-
bility impairment in more than half of patients [1]. For the
last 30 years, a substantial effort has been made to under-
stand the condition of sarcopenia, and several definitions
have been proposed [2]. Sarcopenia has recently been rec-
ognized as an independent condition with its own ICD-10
code [3]. One of the most widely used definitions is by the
European Working Group on Sarcopenia in Older Persons
(EWGSOP): low muscle mass with low muscle strength or
low physical performance [4]. Previous studies on sarcope-
nia in patients with hip fracture have been cross-sectional,
single-center, have included few participants or have had
short follow-ups [5–10]. The three components of EWG-
SOP sarcopenia have different associations with mobility
after hip fracture. Physical performance and mobility are
strong determinants of mobility after hip fracture [11, 12].
Muscle strength is a somewhat weaker predictor [13, 14],
whereas the studies on muscle mass have been inconclusive
[15]. Our primary hypothesis is that sarcopenia, determined
by methods suitable for bed-side use, predicts change in
mobility in the year after hip fracture and therefore that sar-
copenia status is useful for determining prognosis and is a
possible cause of mobility impairment. Further, we aim to
describe the associations of sarcopenia and the individual
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components of sarcopenia (muscle mass, grip strength and
mobility) and adverse clinical outcomes in the year after
hip fracture: change in activities of daily living, reoperations
for hip fracture, all-cause hospitalization, fractures, becom-
ing a resident of a nursing home or death.
Methods
Study design
We conducted a prospective observational study of sar-
copenia in patients with acute hip fracture with follow-
up at three months and one year, conducted at three
Norwegian hospitals in 2011–2013.
Participants
Participants were included while in hospital in the postop-
erative phase. Eligible participants were aged ≥65 years,
able to give informed consent as judged by experienced
clinicians, were living in the community, and were ambu-
latory before the fracture. Patients who were unstable such
as with delirium, acute respiratory failure or in severe pain
were not eligible. Other exclusion criteria were dementia
when it made informed consent impossible, remaining life
expectancy of less than three months and bone disease
other than osteoporosis or osteomalacia. We screened for
participants by examining lists of patients admitted for hip
fracture or staying on the hospital wards.
Data collection
Information was collected by the authors and study
personnel by examination, chart review, routine blood
tests and by interviews with patients and their caregivers
from the first postoperative day and until discharge from
hospital. Weight was measured with the scales on the
hospital wards. We collected the American Society of
Anesthesiologists (ASA) score, Charlson comorbidity
index [16], Barthel activities of daily living (B-ADL)
score [17], length of the acute care hospital stay, previ-
ous hip fracture and type of hip fracture. Follow-up was
at 3 months at an outpatient clinic and at one year as a
telephone interview with the patient or care-giver. Infor-
mation on previous and subsequent hip fractures, and
reoperations for the index hip fracture came from the
Norwegian Hip Fracture Register [18]. This register
started data collection in 2005 and has coverage on an
estimated 90% of all hip fractures in Norway. The regis-
ter has information on reoperations, with an estimated
coverage of 65% of hip fractures treated with surgical
pinning, 68% after hemiarthroplasty and 93% after total
hip replacement [19]. Mortality data was supplied by the
National Population Register, which is complete.
Sarcopenia
Participants were classified as sarcopenic if they had low
muscle mass and either low grip strength or impaired
mobility, as described by the EWGSOP [4]. Total body
muscle mass was determined by anthropometry by the
method of Heymsfield et al. using height, arm circumfer-
ence and triceps skinfold [20]. Arm circumference was
measured on the right arm using a non-elastic tape at
the mid-point of the acromion and olecranon process,
and triceps skinfold was measured on the posterior as-
pect of the same arm at the same level using a skinfold
caliper (Harpenden, Baty International, Great Britain).
Height was measured by a wall mounted stadiometer, or
if the patients was unable to stand self-reported height
was used. If the participant was unable to stand or re-
port their height, the length from heel to crown was
measured while lying in bed. In cases with missing value
on height at baseline, height measured at follow-up was
used. The values for total body muscle mass were trans-
formed to appendicular lean mass (ALM) using model 1
described by Kim et al. [21]. The cut-points for low
muscle mass were ALM ≤7.25 kg/m2 for men and
≤5.67 kg/m2 for women. We chose anthropometry for
its ease of use at the bed-side in immobile hip fracture
patients. Grip strength was measured with a Jamar Hy-
draulic Dynamometer (Sammons Preston, USA) while
the patient was sitting in bed or on a chair with the
elbow flexed, the wrist in the neutral position and with
verbal encouragement. Grip strength was measured
three times on each hand with short intervals between
each attempt while the grip was repositioned. The single
best value out of these six measurements was used. Low
grip strength was ≤30 kg for men and ≤20 kg for
women. Mobility in the two weeks before the hip frac-
ture was determined by interview using the New Mobil-
ity Score (NMS). The NMS is scored 0–9 according to a
person’s ability to walk indoors, outdoors, or while shop-
ping [22]. The cut-point for low mobility was chosen as
< 5, as this has been used to predict mortality after hip
fracture [23]. We used a Danish version of the NMS
with minimal modifications to Norwegian. Sarcopenia
status was determined postoperatively and at follow-up.
Outcome measures
The primary outcome was change in mobility, calculated
as NMS at one year minus the pre-fracture NMS. We
believe that change in mobility is more relevant than
mobility for identifying patients who are more likely to
benefit from interventions. We determined mobility pre-
fracture, at three months, and at one-year. All other ana-
lyses were considered exploratory. Other outcome vari-
ables at one year were NMS at one year, B-ADL at one
year, change in B-ADL, new clinical fractures, new hip
fractures, reoperation for hip fracture, all-cause hospital-
izations, death, becoming a permanent resident of a
skilled nursing home, and the combined endpoint of be-
coming a permanent resident of a nursing home or
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death. The combined endpoint was chosen because
death and becoming a resident of a nursing home are
competing risks. New clinical fracture was any symp-
tomatic skeletal fracture reported by the patient.
Statistical analysis
We report descriptive data as means with standard devia-
tions or as counts with percentages. To examine the pre-
dictive effect of sarcopenia status on changes in mobility
and level of activity of daily living, we used linear regression
analyses with NMS and B-ADL as response variables and
sarcopenia status at baseline (sarcopenic vs. not sarcopenic)
and age, sex and BMI as predictors. Age, sex and BMI were
included in the models because they are established predic-
tors of mobility after hip fracture [24] or sarcopenia [25].
The relationship with age and BMI was not assumed to be
linear and was modelled using restricted cubic splines with
3 knots, placed at the 10%, 50% and 90% quantiles. We as-
sumed that a one-point change in NMS would be clinically
significant. We used Fisher’s exact test for the analysis of
sarcopenia associated with new clinical fracture, new hip
fracture, reoperations, all-cause hospitalization, becoming a
resident of skilled nursing home, and the combined end-
point of nursing home or death. The association between
the separate components of sarcopenia (muscle mass, grip
strength and mobility) with change in mobility, change in
B-ADL and the combined endpoint of becoming a resident
of a skilled nursing home or death was analysed using re-
gression analysis. Muscle mass, grip strength and mobility
were independent continuous variables, and were analyzed
separately. Change in mobility and change in B-ADL were
continuous, dependent variables and the combined end-
point of becoming resident of a nursing home or death was
a dichotomous dependent variable.
For the regression analyses, we used multiple imput-
ation (500 imputations), based on predictive mean match-
ing, using the ‘aregImpute()’ function in the ‘rms’ R
package [26]. The variables used in the imputation models
were the ones included in the regression models, variables
highly correlated with these variables and variables ex-
pected to explain the missing data mechanism: NMS at
baseline, follow-up, and at one year, and change in NMS
from baseline to one year, B-ADL before the hip fracture
and change in B-ADL from pre-fracture until one year,
sarcopenia status at baseline, BMI at baseline, ASA score
during hip fracture surgery, previous hip fracture, serum
albumin when in hospital, grip strength at follow-up, sex,
clinical fractures and hip fractures in the year after admis-
sion, becoming a resident of a skilled nursing home, or
dying in the following year. All continuous predictors
were modelled linearly in the imputation model. The im-
putation analyses were done in R 3.3.0 [27] and the rest of
the analyses were done in Stata 14 (Stata Corp., USA). P-
values ≤0.05 were considered significant.
Results
All patients in hospital with confirmed hip fracture were
considered for inclusion if the research staffs at the different
hospitals were present. Some patients were unable to partici-
pate because they were discharged before the two-day con-
sent process was completed. There was no systematic
recording of the patients who were screened, but not in-
cluded. Figure 1 describes the progress of participants
through hip fracture, inclusion in the study and follow-up.
During the period of inclusion 1592 patients had surgery for
hip fracture and 282 patients were included in the study.
Mean age was 79.4 (SD 8.2) years and 76% were female.
Mean BMI was 24.1 (SD 4.3) kg/m2, with a wide range 13.0
to 44.7 kg/m 2. See Table 1 for baseline demographics. One
patient died during the hospital stay. Participants who had
missing data on sarcopenia status during hospitalization
had lower pre-fracture NMS and pre-fracture B-ADL and
were more likely to become a permanent resident of a
skilled nursing home. For 69 participants, height was not
assessed during the hospital stay, and for 52 of these, height
determined at follow-up was used.
Sarcopenia
Sarcopenia status during hospitalization for hip fracture
was determined in 201 participants, and 39% (77/201)
had sarcopenia. Low muscle mass was present in 66%
(128/194) of the participants, low grip strength in 52%
(116/222), and 8% had low pre-fracture mobility (19/
243). One participant did not have muscle mass deter-
mined but had grip strength and NMS above the cut-
points and was considered not-sarcopenic. Figure 2.
Participants with sarcopenia were older, had lower BMI,
greater ASA score at operation, greater prevalence of
previous hip fracture and pulmonary disease and lower
B-ADL before the fracture. Grip strength and ALM were
assessed at a median of 4 days after surgery (interquar-
tile range 3 to 6 days) (Fig. 2).
Outcomes after one year
Sarcopenia was not associated with change in mobility
at one year in unadjusted or adjusted analyses (e.g., the
change in NMS was an additional 0.2 in sarcopenic pa-
tients compared to non-sarcopenic patients, 95% CI: –
0.5 to 0.9, P = 0.6); see Table 2 for outcomes at one-year.
Sarcopenia status at hospitalization did not predict
change in mobility from pre-fracture to 3 months, or
from 3 months to one-year. Results were not affected by
imputation of missing values. Mobility was reduced in
54% of participants one year after hip fracture, with a
mean NMS of 6.4 (SD 2.2). See Fig. 3 for NMS by sarco-
penia status during the year after hip fracture. Figure 4
describes the relationship between specific scores on the
NMS pre-fracture and at one-year. Participants with sar-
copenia had lower mobility at one-year, NMS 5.8 (SD
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2.3) vs. 6.8 (SD 2.2), P = 0.003, and greater impairment
in B-ADL, 16.8 (SD 4.4) vs. 18.6 (SD 2.8), P = 0.001,
compared to patients without sarcopenia. Sarcopenia
was associated with becoming a permanent resident of a
skilled nursing home (OR 3.2, 95% CI: 0.9 to 12.4, P =
0.048) and the combined endpoint of becoming a resi-
dent of a skilled nursing home or death (OR 3.6, 95%
CI: 1.2 to 12.3, P = 0.02).
Muscle mass, grip strength and mobility
Muscle mass or grip strength was not associated with
any outcome in adjusted analysis Table 3. In unadjusted
analysis, grip strength and NMS were associated with a
reduced risk of becoming a resident of a nursing home
or death. The NMS was positively associated with
change in B-ADL in adjusted analysis (estimate 0.2 per
point, 95% CI 0.0 to 0.4, P = 0.03).
Discussion
The aim of this study was to investigate if sarcopenia
predicted change in mobility after hip fracture. We
found that sarcopenia status did not predict change in
mobility in unadjusted analysis, which indicates that
sarcopenia is not useful in determining prognosis. Fur-
ther, sarcopenia did not predict change in mobility in
analysis adjusted for age, sex and BMI, which indicates
that sarcopenia status is not likely to be causally related
to developing reduced mobility. We used multiple im-
putation to reduce the loss of information associated
with missing values. This approach is considered inferior
to having all the data, but preferable to performing ana-
lysis on complete data. One assumption of multiple im-
putation is that missing values can be estimated by the
remaining information in the dataset. The results of our
analysis were similar when analyzing complete cases and
when analyzing datasets with imputed values, indicating
that the results of our analysis are valid even if this as-
sumption was erroneous.
Change in mobility was not associated with sarcopenia
and this was consistent across all the investigated time
periods, from baseline to three months, from baseline to
one year and from three months to one year. Mobility
from before the hip fracture until one year is character-
ized by an initial loss of mobility and a subsequent par-
tial recovery. Sarcopenia is not associated with either the




after study start, or













































Lost to follow-up (n = 2)
Dead: 2
Lost to follow-up (n = 4)
Dead: 3
Other reasons: 1




telephone at 1 year
n = 71
Follow-up by
telephone at 1 year
n = 120
Follow-up by
telephone at 1 year
n = 67
Fig. 1 Overview of patients with hip fracture, patients included in the study and patients returning for follow-up
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that sarcopenia is not related to change in mobility. In
contrast to change in mobility, being sarcopenic was as-
sociated with having lower mobility pre-fracture, at three
months and at one year, compared to not being sarcope-
nic. This is expected, since low mobility is one criteria
for sarcopenia. As seen in Fig. 4, pre-fracture mobility is
a determinant of mobility at three months and one year.
Savino et al. found that grip strength measured in hos-
pital predicted recovery of walking ability in patients
with hip fracture [13]. In contrast, our findings indicate
that neither muscle mass nor grip strength, when ana-
lysed as continuous variables, were associated with
change in mobility. This indicates that the choice of cut-
points for low muscle mass or low grip strength would
not have changed our results. We found an association
between mobility pre-fracture and change in activities in
daily living, but this was an exploratory analysis and the
effect size was small.
Sarcopenia was associated with an increased probability
of becoming a resident of a skilled nursing home (OR 3.2,
95% CI 0.9 to 12.4, P = 0.048) and the combined endpoint
of becoming a resident of a nursing home or death (OR
3.6, 95% CI 1.2 to 12.3, P = 0.02). This is a clinically relevant
finding but must be interpreted with caution, as it was an
exploratory outcome and we were not able to correct for
age, sex or BMI because of the low number of outcomes.
Among the participants who had sarcopenia status deter-
mined, 6 participants died or became permanent residents
of a nursing home among the not sarcopenic and 12 partic-
ipants among those who were sarcopenic. The NMS was
chosen as our measure of physical performance because we
assumed that many participants would be unable to walk at
inclusion. The NMS is extensively studied as a predictor of
mobility, morbidity, mortality and becoming a resident of a
nursing home [28–31]. We found a ceiling effect with the
NMS, with 54% of participants scoring the maximum 9 be-
fore the fracture and 30% at one-year. Possibly because par-
ticipants with a pre-fracture NMS of 0 or 1 were not
eligible for inclusion. Patients found the NMS easy to
understand and scoring was straightforward. Surprisingly,
we found that 8% of patients had better mobility at one-
year compared to pre-fracture. For some of the patients this
was due to illness that started before the fracture, and their
improvement in mobility after hip fracture was due to reso-
lution of their illness, rather than successful rehabilitation.
Use of rehabilitation services improves mobility after hip
fracture [32, 33]. We did not record what rehabilitation ser-
vices the participants received, and it is possible that re-
habilitation could mediate the effect between sarcopenia
and change in mobility.
The participants in our study were slightly younger (79.4
vs. 80.0 years) and had a lower mean ASA score (2.5 vs. 2.7)
indicating better health compared to patients in the
Norwegian Hip Fracture Register. We did not include
Table 1 Baseline characteristics of participants by sarcopenia status
Not sarcopenic Sarcopenic P-value
Age, years (SD) 77.1 (7.8) n = 124 81.8 (7.6) n = 77 < 0.0001
Female, n (%) 95 (77) n = 124 56 (72) n = 77 0.5
Barthel ADL
pre-fracture (SD)
19.5 (1.1) n = 85 18.7 (1.9) n = 60 0.006




29 (24) n = 123 14 (18) n = 77
Neck of femur,
displaced, n (%)
46 (37) n = 123 31 (40) n = 77
Trochanteric,
n (%)
48 (39) n = 123 32 (42) n = 77
ASA score (SD) 2.3 (0.6) n = 124 2.7 (0.6) n = 77 < 0.001
Previous hip
fracture, n (%)
5 (4) n = 124 9 (12) n = 77 0.039
Charlson score (SD) 0.9 (1.3) n = 124 1.1 (1.3) n = 77 0.15
Heart failure, n (%) 7 (6) n = 124 6 (8) n = 77 0.5
Previous myocardial
infarction, n (%)
14 (11) n = 124 9 (12) n = 77 0.9
Cerebrovascular
disease, n (%)
13 (10) n = 124 8 (10) n = 77 0.98
Diabetes
mellitus, n (%)
9 (7) n = 124 10 (13) n = 77 0.2
Any solid
tumor, n (%)
7 (6) n = 124 8 (10) n = 77 0.2
Pulmonary
disease, n (%)
15 (12) n = 124 18 (23) n = 77 0.036
Length of hospital
stay, days (SD)
6.8 (2.7) n = 124 9.6 (6.7) n = 77 < 0.001
Body composition
BMI, kg/m2 (SD) 25.6 (4.2) n = 107 22.1 (3.7) n = 70 < 0.001
ALM/height2,
kg/m2 (SD)
6.3 (1.5) n = 111 4.4 (1.0) n = 77 < 0.001
Women 6.1 (1.3) n = 86 4.3 (0.8) n = 56 < 0.001




27.0 (10.3) n = 123 16.5 (6.4) n = 77 < 0.001
Women 22.9 (6.9) n = 94 14.3 (5.0) n = 56 < 0.001




8.0 (1.5) n = 123 7.1 (2.0) n = 74 < 0.001
Women 8.0 (1.6) n = 94 7.1 (2.0) n = 55 0.008
Men 8.2 (1.4) n = 29 6.8 (2.2) n = 19 0.017
Baseline characteristics by sarcopenia status (means with standard deviations
and counts with percentages). P-values for comparison of groups are by the
Mann–Whitney–Wilcoxon test, except for type of fracture which is by
chi-squared test. Trochanteric fractures include basocervical femoral neck
fractures and subtrochanteric fractures. Previous hip fracture indicates a
previous hip fracture, either left or right hip. ALM: Appendicular lean mass,
ADL: Activities of daily living
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patients from skilled nursing homes or with severe cognitive
impairment, and our results are not generalizable to those
populations.
Anthropometry is considered a less valid method for
determining muscle mass compared to dual-energy X-
ray absorptiometry (DXA) or computed tomography
scan [34]. The EWGSOP recommends not using anthro-
pometry to determine muscle mass in research but al-
lows for it in clinical practice [4]. We have previously
investigated how anthropometry compares to DXA in
identifying low muscle mass and found an area under
the curve of 0.64 (95% CI 0.54–0.75) in women and 0.72
(95% CI 0.56–0.87) in men [35]. Using anthropometry to
identify low muscle mass instead of DXA can lead to
misclassification of muscle mass status and hence sarco-
penia status. By using anthropometry to determine sar-
copenia status we reduced our ability to detect an effect
of sarcopenia on outcomes. We used anthropometry in
our study because it is in common use [36], inexpensive,
and more easily performed on patients with reduced
mobility and acute illness, compared to DXA [37]. Some
consider objectively measured physical performance su-
perior to self-reported mobility, such as the NMS, but
when the two types of measurement are compared in
Fig. 2 What participants were assessed for muscle mass, grip strength, mobility and sarcopenia
Table 2 Outcomes after one year by sarcopenia status
Marginal values Regression (sarcopenic – not sarcopenic)
Not sarcopenic Sarcopenic Unadjusted Adjusted
Mean (SD) No. Mean (SD) No. Estimate 95% CI P Estimate 95% CI P
Change NMS −1.2 (1.8) n = 117 −1.3 (1.9) n = 67 0.0 −0.6 to 0.6 0.9 0.2 −0.5 to 0.9 0.6
Change B-ADL −0.8 (2.4) n = 76 −2.2 (3.9) n = 52 −0.4 −1.2 to 0.3 0.3 −0.3 − 1.1 to 0.6 0.6
Not Sarcopenic Sarcopenic OR 95% CI P
Fracture, n (%) N 7 (6) n = 120 8 (11) n = 71 2.0 (0.6 to 7.0) 0.3
Hip fractures, n (%) N 3 (2) n = 124 3 (4) n = 77 1.6 (0.2 to 12.5) 0.7
Reoperations, n (%) N 7 (6) n = 124 1 (1) n = 77 0.2 (0.0 to 1.8) 0.2
Hospitalization, n (%) N 41 (33) n = 123 24 (33) n = 73 1.0 (0.5 to 1.9) 1.0
Nursing home, n (%) N 5 (4) n = 124 9 (12) n = 77 3.2 (0.9 to 12.4) 0.048
Death, n (%) N 3 (2) n = 124 5 (6) n = 77 2.8 (0.5 to 18.5) 0.3
Death or nursing home, n (%) N 6 (5) n = 124 12 (16) n = 77 3.6 (1.2 to 12.3) 0.02
Outcomes after one year by sarcopenia status (sarcopenic – not sarcopenic). Regression analysis for change in mobility and Barthel ADL from pre-fracture until
one year adjusted for age, sex and BMI with imputation of missing values. ADL: Barthel Activities of daily living. Analysis for fracture, hip fracture, reoperations,
all-cause hospitalization, nursing home, death or nursing home or death by two-sided Fisher’s exact test using available cases. NMS: New mobility score. B-ADL:
Barthel activities of daily living. OR: Odds ratio
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Fig. 3 New Mobility Score (NMS) during hospitalization, at three months, and at one year, stratified by sarcopenia status during hospitalization.
The horizontal lines show mean NMS scores
Fig. 4 New Mobility Score (NMS) pre-fracture and at one-year follow-up. The first number in each cell is the number of patients with the given
combination of NMS scores. For each row, the percentage values and the cell shadings show the distribution of NMS at follow-up for a given
NMS score at baseline. No patients had a NMS of 1 at baseline, and patients with a NMS score of 0 was excluded from the study. Patients with
the same NMS score at baseline and follow-up are shown in boldface, and any cell to the right of this diagonal indicates an improvement in
the NMS
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hip fracture patients they have been found to be equally
predictive of outcomes [38]. Future research on sarcope-
nia in hip fracture patients could explore other methods
for determining sarcopenia, such as computed tomog-
raphy to directly measure intramuscular adipose tissue
[34] or using objective measures of physical performance
such as the Short Physical Performance Battery [39]. A
randomized controlled study of an intervention targeting
sarcopenia status to improve mobility after hip fracture
would provide additional insight on the causal relation
between sarcopenia and mobility.
The included patients were a minority of all patients
operated on for hip fracture during the period of
inclusion. We included postoperative patients who were
frequently bed-bound, receiving opiates for pain relief,
with indwelling urinary catheters and while receiving
intravenous fluid therapy. We believe there were three
main reasons for the low recruitment rate: patients did
not fulfill the inclusion criteria, patients were discharged
before the consent process could be completed, and
participants declined to participate because it was too
much of a burden. For the patients who did consent to
participate we found that determining sarcopenia by
anthropometry, grip strength and the NMS was feasible.
The greatest difficulty was in determining the height of
the participants.
Conclusion
Sarcopenia status determined in postoperative hip frac-
ture patients by anthropometry, grip strength and self-
reported mobility did not predict change in mobility in
the year after hip fracture. Sarcopenia was associated
with having lower mobility at one year and a greater risk
of becoming a resident of a nursing home or death.
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